Comparison of the Efficacy of Ondansetron and Aprepitant for the Prevention of Postoperative Nausea and Vomiting: A Double Blinded Randomized Control Trial in Patients Undergoing Mastectomy/Thyroidectomy by Salome, Jeyabalan
1 
 
 
 
COMPARISON OF THE EFFICACY   OF ONDANSETRON AND 
APREPITANT FOR THE PREVENTION OF POSTOPERATIVE 
NAUSEA AND VOMITING – A DOUBLE BLINDED RANDOMIZED 
CONTROL TRIAL IN PATIENTS UNDERGOING MASTECTOMY/ 
THYROIDECTOMY 
 
 
 
 
 
 
 
 
 
This dissertation is in partial fulfilment of the requirement for the M.D. Degree (branch X) 
Anaesthesiology examination of the Tamil Nadu Dr. M.G.R. Medical University, Chennai, to 
be conducted in April 2013. 
2 
 
                                         CERTIFICATE                      
 
This is to certify that the dissertation entitled "comparing the efficacy of aprepitant and 
ondansetron for the  prevention of postoperative nausea and vomiting – a double  
blinded randomized control trial in patients undergoing mastectomy / thyroidectomy " 
is a bonafide original work of Dr. Salome Jeyabalan, towards the M.D. Branch X  
( Anaesthesiology ) Degree examination of the Tamil Nadu Dr. M.G.R. Medical university, 
Chennai, to be conducted in April 2013. 
 
Signature of the Guide and H.O.D. 
 
 
Dr. Kunder Samuel Prakash,                                                  Dr. Mary Korula, 
Assosiate Professor,                                                                Professor and Head, 
Department of anaesthesia,                                                  Department of anaesthesia, 
Christian Medical College & Hospital,                                 Christian Medical College & 
Hospital, 
Vellore – 632004.                                                                   Vellore – 632004. 
 
 
3 
 
                    ANTI PLAGIARISM  CERTIFICATION 
 
 
4 
 
                                     ACKNOWLEDGEMENTS 
 
• I would like to express my sincere gratitude to my guide, Dr. Kunder Samuel 
Prakash, Assosiate Professor, Department of Anaesthesiology, for his meticulous 
guidance, immense patience, and valuable advice while guiding me through this 
study. Indeed, without his ideas, help, support and amazing computer abilities this 
study would have never been possible. 
• I would like to thank my co-guide Dr. Suma Mary Thampi, Assistant Professor, 
Department of Anaesthesiology, for all her ideas, suggestions, encouragement and 
help in enabling me complete this study. 
• I am grateful to Dr. Mary Korula, Professor & Head and the entire Department of 
Anaesthesiology, including faculty, colleagues, and technicians,  for  all  the  support  
rendered  in  preparing  this  dissertation. 
• I am also thankful to the Department of Endocrine Surgery for graciously allowing 
access to their patients & rendering their co operation in doing this study. 
• I am grateful to Dr. Annadurai and staff, manufacturing section, Department of 
pharmacy, Christian Medical college and hospital, Vellore for their invaluable help in 
preparing the study drugs. 
• I express my sincere thanks to the entire team of the O5East ward for their 
invaluable help in carrying out this study. I would not have been able to complete this 
study if it had not been for the enthusiastic co operation of the nursing staff of the 
O5East ward. 
5 
 
• I extend my thanks to Dr. B.Antonisamy, Department of Biostatistics, for his help 
with the statistical analysis and patiently clarifying all my doubts. 
• I sincerely thank Dr. Reddy’s laboratories, for supplying the bulk drug aprepitant. 
• I wish to thank all my patients for their co-operation in this study. 
• I would like to thank my family for their love, encouragement & constant support 
without which I would not have reached this far. 
• I would finally and most importantly like to thank God, who has lead me this far, and 
will surely lead me onward. 
 
 
 
 
 
 
 
 
 
 
 
6 
 
                                                 CONTENTS 
 
 
 Page Number 
1.  Aim                                                                              7 
2.  Objectives                                                                    8 
3.  Introduction                                                                 9  
4.  Review of Literature                                                   12  
5. Patients and methods                                                   64  
6.  Results                                                                        73  
7.  Discussion                                                                  83  
8.  Limitations                                                                 88  
9.  Conclusions                                                               89  
10.  Bibliography                                                              90  
11.  Appendix                                                                   105 
 
 
 
 
 
 
 
 
7 
 
                                                       AIM 
 
 
 
The aim of this study is to compare the efficacy of ondansetron and aprepitant in the 
prevention of postoperative nausea and vomiting in women undergoing mastectomy and 
thyroidectomy. 
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                                               OBJECTIVES 
 
 
 
• To compare the antiemetic efficacy of ondansetron and aprepitant  in the prevention                         
of postoperative vomiting in female patients undergoing mastectomy / thyroidectomy. 
 
• To evaluate the severity of postoperative nausea, number of episodes of vomiting, 
timing of the first vomiting episode and use of rescue antiemetics in thyroidectomy 
and mastectomy patients receiving ondansetron or aprepitant as antiemetic. 
 
• To assess if the patients satisfaction in the management of postoperative nausea and 
vomiting improves with this intervention. 
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General anaesthesia is a pharmacological depression of the neurological system that   results 
in temporary loss of response to various external stimuli.  
 
Postoperative nausea and vomiting (PONV) is an unpleasant side effect of general 
anaesthesia. They together are the second most common complaints reported. The causative 
factors of PONV are varied which includes patient related, operative and anaesthesia related 
factors. Post operative nausea and vomiting (PONV), despite the advances in anaesthetic care 
is still a problem, following certain types of surgery in the high risk population. 
 
Presently, the overall incidence of PONV varies with the types of operative procedures and 
with the patient groups and is approximately 25 to 30%. A simple score to predict PONV was 
devised by Apfel et al. The risk factors included are : women, previous history of travel 
sickness or PONV, non-smokers, and those who receive opioids postoperatively 
 
 Depending on the Apfel risk score, the PONV incidence was precicted as 10% for a score of 
0, 21% for a score of 1, 39% for a score of 2, 61% for a score of 3 and 79% for a score of 4. 
  
The incidence of PONV following mastectomy is reported to be 60 to 80%when no 
prophylactic antiemetic is given, but it can still be as high as 20 to 30% despite the 
administration of ondansetron.  
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 Similarly, patients undergoing various thyroid surgical procedures have a high percentage of 
PONV because most of them are women and due to several surgical causes. PONV is 
frequently listed by patients as the most distressing concern in the post operative period, 
sometimes even exceeding the pain of surgery. The growing awareness to improve patient 
satisfaction has prompted to strive for a post operative period free of nausea and vomiting. 
 
 Aprepitant belongs to the class of Neurokinin 1 receptor antagonist. It is highly selective for 
neurokinin receptors and its half life is long.. It is demonstrated to be effective against emesis 
induced by opioids and chemotherapeutic drugs. In patients having open abdominal surgical 
procedures and craniotomy, studies have shown that aprepitant had more antiemetic effect 
than ondansetron in preventing vomiting in the postoperative period. This study was an effort 
to compare the antiemetic efficacy of ondansetron and aprepitant in women undergoing 
mastectomy and thyroidectomy.                                
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                                     NAUSEA AND VOMITING 
 
Nausea and vomiting are protective reflexes that occur as defence mechanisms against the 
intake of harmful substances. In fact, vomiting was a recognised effective treatment tool in 
older civilization(1). 
Nausea is an uncomforable feeling which leads to a tendency to vomit. 
Retching is an effort to vomit which is not under voluntary control, but these efforts do not 
cause does not cause expulsion of stomach contents through the oral cavity.  
During vomiting, motor changes occur in the muscles of the abdomen and respiration and is 
coordinated by the brain stem (1). 
 
Phases of vomiting (2)  
Retching phase 
The abdominal muscles undergo a few coordinated contractions together with the diaphragm 
and inspiratory muscles. 
Expulsive phase 
During this phase glottis closes, contraction occurs in the abdominal muscles, diaphragm, 
oesophagus and relaxation occurs at the sphincter which is present the junction of the 
oesophagus and stomach. This leads to evacuation of the stomach contents that is aided by a 
backward contraction of the upper oesophagus and decreases in tone of the diaphragmatic 
portion that encircles the oesophagus and this aids in the process of vomiting(3). 
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Fig 1: THE ACT OF VOMITING (4) 
 
 Vomiting is a uncomfortable act that occur with many procedures. Vomiting is  a major 
problem during recovery from various operations , in cytotoxic anticancer chemotherapy and 
in situations involving motion and vestibular disturbances(5). 
 
 
 
VOMITING AND ASPIRATION 
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Under normal circumstances, the protective reflexes such as gag and cough reflex prevents 
aspiration of gastric contents thereby preventing aspiration pneumonia or asphyxiation. 
However these protective reflexes are compromised in certain situations like alcohol 
influence or under anaesthesia where vomiting can be dangerous(6). 
 
During anaesthesia, depression of airway reflexes places patients at increased risk of for intra 
operative pulmonary aspiration or for aspiration during the recovery period. Pulmonary 
consequences from perioperative aspiration fall into 3 categories- particle related, acid related 
and bacterial contamination.  
 
Particle related – Acute airway obstruction can cause immediate death due to arterial 
hypoxemia of asphyxiation. Immediate intervention requires prompt removal of aspirated 
matter, oxygenation of the patient and tracheal intubation to prevent further aspiration. 
 
Acid related – The ill effects of acid aspiration occurs in two phases. Immediate direct tissue 
injury occurs initially and subsequently followed by an inflammatory response. A chemical 
burn occurs within a few seconds from the central airways to the alveoli. Within a few hours, 
desquamation of the superficial cell layer with complete loss of ciliated and non ciliated cells 
occurs. After three days, regeneration is seen and complete recovery occurs in 7 days.  
 
 The alveolar type 2 cells are very sensitive to hydrochloric acid and degenerate within 4 
hours of acid exposure. An increase in lysophosphatidyl choline occurs within 4 hours after 
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acid aspiration and leads to an increase in alveolar permeability and increase in lung water. 
This leads to an increase in ventilation-perfusion mismatching, decrease in lung compliance 
and increase in the alveolar arterial oxygen tension difference.  
 
 The second phase includes acid mediated induction and release of pro-inflammatory 
cytokines like tumour necrosis factor alpha and interleukin-8. These will in turn trigger the 
expression of adhesion molecules on the endothelium thus promoting a neutrophilic 
inflammatory response.  
 
The morbidity increases directly with the volume and inversely with the pH of the acid 
aspirate. In severe cases, epithelial degeneration, interstitial and alveolar oedema and 
hemorrhage into the alveolar spaces rapidly progresses to ARDS with high permeability 
pulmonary oedema.  
 
Destruction of pneumocytes, decreased surfactant activity, hyaline membrane formation and 
emphysematous changes can follow, leading to V/Q mismatching and reduced compliance. 
Destruction of the microvasculature increases pulmonary vascular resistance and dead space 
ventilation. Thus gastric aspiration combines a particulate injury causing foreign body 
reaction and focal inflammatory changes and a diffuse acid damage. Both together contribute 
to increase alveolar capillary leak. 
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Bacteria related- the gastric contents are not sterile and mixed with aerobic-anaerobic 
bacteria resulting in pneumonia. Gram negative and ventilator acquired pneumonias many of 
which are caused by aspiration of oropharyngeal secretions and gastric contents are 
significant determinants of death in post operative pneumonia(5). 
 
MENDELSON’S SYNDROME 
 
Mendelson’s syndrome or aspiration pneumonitis was first described in obstetrical cases by 
Curtis Lister Mendelson who was a practising obstetrician in New York. In his classic paper, 
he explains about the lung manifestations in obstetric patients caused by aspirating the 
stomach contents. Typically there is history of vomiting after inhalational anaesthesia, either 
intraoperatively or in the early postoperative period. Within a few hours of aspiration, there is 
sudden onset of dyspnea, cyanosis, tachycardia and shock. Examination reveals generalised 
adventitious breath sounds and bronchospasm, but no localised signs of lung disease.  
 
 The presentation simulates pulmonary oedema with extensive ronchi and rales in both lungs. 
Tachycardia and tachypnea  are common findings. In extreme cases, gross pulmonary 
oedema may supervene and can even have rapid deteriorating course leading to death from 
cardiac failure. Chest X ray reveals soft patchy mottling throughout the lung fields. 
Mendelson  showed that acid content of the stomach was responsible for the asthma like 
syndrome(7). 
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POST OPERATIVE NAUSEA AND VOMITING- PONV 
 
It is the uncomfortable feeling of nausea or the act of vomiting that occurs during the first 
postoperative day(8). 
Predisposing factors for vomiting / regurgitation and aspiration(6). 
1. Emergency surgeries 
2. Light plane of anaesthesia / unexplained response to stimulation 
3.  Upper or lower GI pathology- acute or chronic 
4. Obese patients 
5. Premedication with opioids 
6.  Impaired conscious level due to neurological disease or sedation 
7. Patient position- lithotomy  
8. Difficult airway or difficult  intubation 
9. Gastrointestinal reflux disease 
10. Hiatus hernia 
 
 
NEUROCIRCUITRY INVOLVED IN EMESIS 
The centre of vomiting in the CNS co-ordinates this complicated act of  emesis. This centre is 
an ill defined area located in the lateral medullary reticulum, proximal to the fourth ventricle  
of the cerebrum. The chemoreceptor trigger zone is situated close to the medullary structure 
calles as area postrema. Dopamine, histamine, muscarinic and opioid receptors are included 
in the chemoreceptor trigger zone (8). 
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Vomiting can be triggered bynumerous signals. The vomiting centre receives inputs from the 
vestibular system, cerebellum, solitary tract nucleus, higher cortical centres, 
glossopharyngeal nerve and the vagus nerve.  
 
These inputs induce areas involved in the causation of emesis. Another signal to the vomiting 
centre is from the chemoreceptor trigger zone that is situated in the medullary area which is 
outside the cerebrospinal fluid-blood barrier. This highly vascularised structure detects 
vomiting causing substances in the blood and cerebrospinal fluid. In addition  Serotonin is 
released by the enterochromaffin cells of the gastrointestinal tract which  bind to 5-HT₃ 
receptors. This causes the afferent neurons of the vagus nerve in the stomach and intestine to 
be stimulated which conduct impulses that reach the area postrema in the brain stem. 
  
Neurons from the area postrema send impulses to the nucleus of the solitary tract. The 
vestibular, limbic and gastrointestinal systems also send impulses to the nucleus of the 
solitary tract.. Efferent neurons from the nucleus of the solitary tract reach the ambiguous 
nucleus located in the dorsal medulla, the anterior respiratory group and the posterior motor 
nucleus of the vagus. Thus, the main  structures included in the act of vomiting are scattered 
in the lower half of the brainstem. These structures are located in the Bolzinger area which is 
located in the brain stem and is involved in co-ordination of respiratory rhyth  and are called 
as the central area involved in the generation of  vomiting.  
 
The receptors involved in the transmission of nausea and vomiting impulses include 
serotonergic (5HT3), dopaminergic (D2), histaminergic (H1), cholinergic (muscarinic)  and 
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neurokinin (NK1) systems(9). Post operative nausea and vomiting is due to various factors 
that  can be triggered by several receptors at central or  peripheral areas. 
 
RISKS INVOLVED 
 
A number of anaesthesia-related, patient-specific and procedure-related  reasons are 
implicated in the occurrence of PONV(11). 
 
NON ANAESTHETIC CAUSES 
              -PATIENT RELATED 
             -SURGERY RELATED 
 
ANAESTHESIA RELATED FACTORS 
            -PREMEDICATION 
           -ANAESTHETIC TECHNIQUES 
          -GENERAL ANAESTHETIC AGENTS 
          -REVERSAL AGENTS 
 
  
21 
 
POST OPERATIVE FACTORS 
          -PAIN 
         -ORAL INTAKE 
        -AMBULATION 
        -OPIOIDS 
 
NON-ANAESTHETIC FACTORS 
PATIENT RELATED FACTORS 
 
Many patient related causes have been recognised which affect the occurrence of emesis 
in the postoperative period. 
This includes patient’s age, history of PONV, gender, phase of the menstrual cycle, 
history of motion sickness, preoperative anxiety, history of morning sickness, co-existing 
medical conditions, non-smoking, degree of dehydration, associated medical conditions 
and metabolic abnormalities like uremia, diabetes mellitus, raised intra cranial pressure, 
acid peptic disease, electrolyte imbalances and exposure to emetogenic drugs like 
digoxin, ergometrine(2,12,13). 
 
      AGE 
In adults, as age increases there are a decreasing incidence of PONV. Age decreases the 
chances of PONV by 13% for every 10 years increase(14,15). In children the incidence of 
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PONV increases with age, reports of PONV being relatively low in less than 3 years of 
age. Reduced autonomic reflexes with increasing age may be an underlying 
mechanism(11,16,17). 
 
HISTORY OF PONV, TRAVEL SICKNESS & MORNING SICKNESS.  
 
The PONV occurrence increases by 3 fold in individuals who had increased vomiting in the 
postoperative period during the previous operations (2, 15, 18–20). In one study, the author 
has reported an increasing occurrence of PONV in individuals who had  previously 
experienced morning sickness(21). 
 
GENDER 
 
 The incidence of PONV is approximately 3 times more common in women. (2,20,22–24). 
However, this gender difference is not seen in patients beyond the 8th decade of life and in the 
preadolescent age group. This suggests that the higher occurrence of emesis in female 
patients may be due to changes in the amount of serum gonadotropin or other hormones 
during their menstrual cycle.  
 
In a recent systematic review by Apfel et al, female gender was found to be the strongest 
overall predictor of PONV. The exact mechanism causing women to experience greater 
vomiting postoperatively is not clear(11). 
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PHASE OF THE MENSRUAL CYCLE 
 
Post operative nausea and vomiting seems to increase around the time of menarche (25) and 
is decreased around the time of menopause(26). In post operative nausea and vomiting, the 
stage of menstrual cycle may also alter the occurrence of nausea and vomiting in the 
postoperative period(27).  
 
Earlier trials have demonstrated a greater occurrence of nausea and vomiting postoperatively 
in women during the first 8 days of their menstrual cycle. The exact mechanism of this 
greater occurrence of PONV is unknown. The postulated explanation is that, the changing 
concentrations of FSH or oestrogen, or both, seem to sensitize the vomiting centre or 
chemoreceptor zone or both(28).  
 
Honkavaara et al suggested that the incidence of PONV is higher during the luteal phase or 
the periovulatory period(29).  Beattie et al reported a four -fold increase in the occurrence of 
nausea and vomiting in the postoperative period in female patients during menstruation (27).  
 
The incidence of PONV also increases if the menstrual cycles are irregular(30). In a later 
study done by Gratz et al, no relationship was found between the stage of the menstrual cycle 
and the incidence of emesis(31). Similarly a systematic review disproved that the 1 to 7 days 
of the menstrual cycle increases the susceptibility to PONV(11,32). A recent systematic 
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review of prospective studies to identify independent predictors of PONV found insufficient 
evidence for menstrual cycle as a risk factor in the incidence of PONV(11). 
 
OBESITY 
  
A positive correlation between obesity and higher incidence of post operative nausea and 
vomiting is known to exist(33). The explanation given to this relationship is that fat 
causes accumulation of volatile anaesthetics and they continue to enter the blood stream 
from there even after discontinuing the administration of inhaled anaesthetics(2,19). 
Other likely explanations are an increased incidence of gastro-oesophageal reflux disease 
and larger residual gastric volume.  
 
Obese individuals have a  higher incidence of airway difficulties and gastric insufflation 
occurs  in an attempt to maintain adequate airway during bag mask 
ventilation(2).However, some studies found no correlation between body habitus and post 
operative nausea and vomiting(14,20). 
 
NON-SMOKERS 
 
The occurrence of PONV is found to be greater in non-smokers compared to smokers. 
Smoking seems to have a protective effect against the incidence of post operative nausea and 
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vomiting(2,12).  Smoking  habit seems to reduce the likelihood of the incidence of PONV by 
one third(14, 15, 34). 
                   
The exact underlying mechanism behind the anti-emetic effect of smoking is not known so 
far. One postulation is that long term contact with cigarette smoke which contains polycyclic 
aromatic hydrocarbons causes induction of CYP2E1 of the cytochrome P450 enzymes which 
are responsible for first pass (phase 1 ) metabolism of volatile anaesthetics(16, 17, 35). 
However, since only a limited fraction of inhaled anaesthetics get metabolised (0.02% of 
desflurane, 0.2% of isoflurane ) it seems unlikely that liver enzyme induction accounts for 
such a large difference in the nausea and vomiting that occurs between individuals who 
smoke and those who do not smoke (11). 
 
Brattwall et al, suggested similar effect from regular sniffing of tobacco. This observation 
suggests that some substance in tobacco is responsible for the previously described effect of 
PONV reduction among smokers(36). 
 
 
PREOPERATIVE ANXIETY 
 
Preoperative anxiety is predicted as a risk factor for post operative nausea and vomiting. 
Preoperative anxiety is a common component of undergoing a surgery. There is a higher 
occurrence of nausea and vomiting in the postoperative period in such anxious individuals. 
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(37). Increased level of catecholamines in such patients is suggested to be a contributing 
factor. Other reason postulated is the excessive air swallowing seen in anxious patients, 
which increases the gastric volume(2). 
 
SURGICAL FACTORS 
 
OPERATIVE PROCEDURE 
After general anaesthesia, the occurrence of nausea and vomiting in the postoperative period, 
is found to be high after certain types of surgeries namely laparoscopic surgeries, 
gynaecological surgeries, breast surgeries, thyroid surgeries, middle ear procedures, 
orchidopexy and strabismus surgery(2, 38- 42).  
 
 PONV can be caused by many factors including gender, age, history of motion sickness, 
obesity, surgical procedure, anaesthetic technique, vagal afferent stimulation during 
manipulation of the gut, increased middle ear pressure due to the use of nitrous oxide and 
traction of the extra ocular muscle which stimulates the oculogastric reflex(9, 40-44).  
 
THYROID SURGERY 
 
The main reason for the increased incidence of nausea and vomiting in patients undergoing 
thyroid surgery is entirely not known. Since most patients undergoing thyroid procedures are 
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middle aged women, it is suggested as  one of the main reasons. Another reason may be due 
to stimulation of the tenth cranial nerve during surgical handling of the neck. 
 
 PONV causes adverse consequences in post thyriodectomy patients, because vomiting can 
result in oozing from the operated area. This oozing if worsens, can cause tracheal 
compression and can cause quick onset obstruction of the airway. This may require 
endotracheal intubation and re-exploration of the operated area. Hence it is appropriate that 
PONV prevention instead of treating it after PONV has occured(40–43). 
 
BREAST SURGERY 
 
Approximately 60 % of patients undergoing breast surgery experience emesis in the 
postoperative period(44–46). More than 60 % of patients undergoing mastectomy along with 
axillary lymph node dissection experience nausea and vomiting in the postoperative period 
when they do not receive antiemetic medication(46,47) and about 10 to 50 % of them have 
emesis in spite of receiving  one or two component prophylaxis for PONV(45,48,49).  
Women undergoing surgeries on the breast by themselves are at increased risk, since being 
female is an important predictor for a higher incidence of PONV (15,20). 
 
The causes of increased emesis following anaesthesia for various surgical procedures of the 
breast is not clear. It is dependent on multiple factors which include obesity, age, operative 
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procedure, history of motion sickness and/or previous PONV, phase of menstrual cycle, 
anaesthetic technique, postoperative pain and psychological factors. 
 
The causes in many emetic syndromes comprise estrogen. In the breast tissue, hormones 
influence the various receptors present. A clear association between   PR positive breast 
cancer in postmenopausal women and trend towards greater estrogen concentration was 
found. (50). The higher estrogen levels in the serum of post menopausal women has been 
correlated to the cancer of breast tissue. In female patients aged more than 50 years, the 
postoperative emesis is correlated with the presence of estrogen receptors(44). 
 
In premenopausal women, due to the cyclical variation of hormonal levels, the changes in the 
ovary due to chemotherapeutic agents and the presence of various receptors influence the 
occurrence of nausea and vomiting in the postoperative period. 
 
DURATION OF SURGERY 
 
Duration of general anaesthesia greater than 4 hours is known to have increased emesis in 
the postoperative period(32,51). This increased incidence is explained as being due to the 
use of parenterally administered drugs and volatile agents. Since patients are administered 
these lipid soluble agents for a long time, they experience greater emesis in the 
postoperative period.(2). 
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ANAESTHESIA RELATED FACTORS 
 
PREMEDICATION 
 
Opioids  when given as premedication can stimulate the CNS opioid receptors and increase 
the incidence of PONV(2). They can directly stimulate the area postrema causing PONV. 
Opioids decrease the gastrointestinal motility thereby prolonging the gastric  emptying time. 
Opioids sensitise the regions in the vestibular area to movement thus predisposing to 
PONV(2,19,34). Atropine or scopalamine concurrently administered as premedication with 
opioids decreases the incidence of emesis after opioid administration(2). 
 
Benzodiazepines like midazolam and lorazepam used as premedication decreases the PONV 
incidence by decreasing the plasma catecholamine levels(52,53). 
 
 
ANAESTHETIC TECHNIQUES AND AGENTS 
 
The occurrence of nausea and vomiting in the postoperative period is affected by the type of 
anaesthetic administered. Emesis  is less after neuraxial blockade provided complications like 
decreased blood pressure and high sympathetic inhibition are prevented, as emetogenic 
agents such as volatile anaesthetics and opioids are not used. Since anaesthesiologists often 
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use a combination of drugs during an anaesthetic, it is difficult to point out an individual drug 
as the cause of PONV and it is more of a combined effect of the drugs used(2,19). 
 
      GENERAL ANAESTHESIA 
 
VOLATILE   ANAESTHETIC AGENTS 
 
 Older anaesthetic agents like cyclopropane and diethyl ether were associated with emesis of 
approximately 80 %. This high occurrence of emesis was related to the greater levels of  
endogenous catecholamines associated with these older anaesthetic  agents. They caused 
more emesis compared to the  potent volatile anaesthetics used in current 
practice(2,12,18,19). 
 
The occurrence of emesis after exposure to the currently used volatile agents is the 
same(2,16,19).Thus the use of volatile agent itself is a high risk factor for the incidence of 
PONV(11,16,54–57). In fact, inhalational anaesthetic agents are implicated as the greatest 
risk for the occurrence of emesis postoperatively(11). 
 
 NITROUS OXIDE 
 Nitrous oxide has anaesthetic characteristics but it causes greater emesis in the postoperative 
period.(58). Several mechanisms have been suggested as contributing factors in increasing 
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the postoperative emesis associated with nitrous oxide. a) increase in middle ear pressure by 
diffusion and stimulates the vestibular apparatus(58,59). b) transfer of nitrous oxide into the 
bowel causing gaseous distension. c) stimulation of dopamine receptors in the CTZ d) action 
on the receptors that are sensitive to opioids(58,60,61).  
 
The incidence of emesis in the postoperative period, increases with increasing concentrations 
of nitrous oxide(58). Thus omitting nitrous oxide contributes to decreasing nausea and 
vomiting when followed as part of other strategies to decrease its occurence(58,60,62,63). 
 
INTRAVENOUS   ANAESTHETIC   AGENTS 
 
 Ketamine when used for induction and / or maintanence of anaesthesia causes a higher 
incidence of PONV compared to patients receiving barbiturates. The release of endogenous 
catecholamines may cause this emetic effect(2).  
 
Propofol is an anaesthetic solution administered intravenously. These days it is used not only 
for inducing anaesthesia but also for maintaining anaesthesia because it has a fast onset and 
recovery profile and low incidence of PONV(64). 
 
Several studies have proved that  total intravenous anaesthesia with propofol alone is 
associated with less emesis compared to other techniques. (65,66).  Propofol is also known to 
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have antiemetic properties. This is attributed to its central antiseratoninergic action(2,67).  
Propofol induction is known to cause less emesis after surgery compared to thiopentone(68).  
 
A balanced anaesthetic technique using opioid-nitrous oxide-relaxant causes greater emesis in 
comparison with total intravenous anaesthesia. This increase in the incidence of emesis is 
attributed to the use of opioid-nitrous oxide combination which has a direct action on the 
chemoreceptor trigger zone(2,18,19,34). 
 
REVERSAL AGENTS  
 
Use of anticholinesterase agents for the reversal of muscle relaxation may cause emesis 
postoperatively. This occurred only when neostigmine was used in doses higher than 2.5 
mg(2,63,69).The muscarinic effect of these drugs cause movement of the gut which adds to 
the occurrence of postoperative emesis. This minor effect is decreased when anticholinergic 
is used along with neostigmine(2). 
 
 
REGIONAL ANAESTHESIA 
 
In central neuraxial blockade techniques such as spinal and epidural, the occurrence of nausea 
and vomiting is approximately 10 to 20%(18). This incidence is higher compared to local 
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anaesthetic inhibition of impulse conduction in the peripheral nerve because neuraxial 
anaesthesia is associated with sympathetic inhibition which contributes to the fall in blood 
pressure which induces emesis (2). In one study it was observed that the nausea and vomiting 
in these patients is reduced by administering 100% oxygen, suggesting that hypoxemia at the 
vomiting centre was the stimulus for vomiting(70).  
 
Several aetiological factors contribute to the occurrence of emesis in obstetric cases. The 
factors include fall in blood pressure,compression of great vessels, strong vagal stimulation 
due to handling of the viscera during surgery and various drugs used intraoperatively such as 
opiates and uterotonics such as oxytocin and particularly ergometrine. Most postoperative 
analgesia regimens include opiates which contribute to PONV(71). 
 
Intrathecal or epidural administration of opioids increases the incidence of PONV than when 
local anaesthetics are used alone. This emetogenic  effect of intrathecal opioid is attributed to 
its rostral spread to the vomiting centre and the CTZ. The agents with higher lipid solubility 
have less rostral spread than the less soluble agents such as morphine(2). 
 
POSTOPERATIVE FACTORS 
PAIN 
 
Pain in the postoperative period is found to significantly contribute to nausea and vomiting. 
This is supported by the fact that regional nerve blocks when used for postoperative analgesia 
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significantly reduces the incidence of PONV(72,73). It is also reported that pain relief is 
associated with the relief of nausea. The  incidence of PONV in association with pain is 
especially higher with pelvic or visceral pain(74). 
 
AMBULATION 
 
Changes in position like sitting up or transport to the post anaesthesia care unit can cause 
sudden movement that can precipitate vomiting in patients who have received opioids, due to 
sensitisation of the vestibular  system(34). Afferent impulses sent from the vestibular 
apparatus reach the chemoreceptor trigger zone via the histamininergic and the cholinergic 
fibres and may cause emesis following ambulation in the postoperative period(75). 
 
ORAL INTAKE 
 
Traditionally it is believed that following all abdominal surgeries, there is inhibition of GIT 
activity for a short period. This clinical phenomenon has been proposed to be caused by 
excessive sympathetic tone, stimulation of nerve fibres and the neurochemical substances that 
cause inhibition of GIT. So it was believed that if patient starts orally soon after surgery, it 
can cause emesis and aspiration,wound dehiscence and anastamotic leakage. However a 
Cochrane review done in 2009 reported an  greater occurrence of nausea but the occurrence 
of  vomiting or paralytic ileus after early intiation of oral or enteral feeding was not 
different(76). 
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OPIOIDS 
 
Opioid  compounds, irrespective of the route of administration cause emesis as common side 
effects in the postoperative period(2,19,34). Opioid analgesia primarily involves central 
receptors in the brain stem and in the rostral anterior cingulate  cortex. However peripheral 
opioid activity at the gut receptors inhibits acetylcholine release from  the mesenteric nerves 
which causes reduction of gut motility and tone. This leads to delayed gastric emptying and 
this triggers nausea and vomiting through a serotonergic signalling pathway(11). 
 
COMPLICATIONS OF PONV 
 
PATIENT RELATED 
 
Although postoperative nausea and vomiting is usually self limiting, it  decreases patient 
comfort and  satisfaction(11,12). Many studies involving high risk populations have 
clearly shown an increase in patient satisfaction with prophylactic antiemetic regimens 
when compared to placebo with rescue antiemetic in the post anaesthesia care unit(77,78). 
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MEDICAL 
 
PONV causes interruption of oral drug therapy, nutrition, diet which can lead to 
dehydration, electrolyte imbalances like hypochloremia, hyponatremia, hypokalemia, 
metabolic alkalosis, increased postoperative pain and orthostatic hypotension(2,8,17,18).  
 
SURGICAL 
 
PONV leads to several surgical complications like venous hypertension, bleeding, 
hematoma formation, disruption of surgical anastamosis, grafts, flaps, wound dehiscence 
and haemorrhage, hematoma formation, increased intracranial and intraocular pressures, 
aspiration pneumonia and oesophageal tears or rupture, the most severe complications 
being rare(2,8,17,18). 
 
ANAESTHESIA RELATED 
 
Approximately 20 % of patients have emesis in the post anaesthesia care unit(8,14,33,83). 
Aspiration of gastric contents can occur in patients who are under the effect of residual 
anaesthetic(2,18,19). 
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ECONOMIC BURDEN 
 
PONV and its resulting complications increase unexpected hospital admission in day care 
surgeries, nursing care time, delay discharge from the post anaesthesia care unit, increase 
the length of hospital stay, thus imposing an economic burden on the hospital resources 
and delaying return to work(2,8,11,18). 
 
PREDICTION OF PONV 
 
Patient related factors like age, gender, non-smoking status, past history of motion 
sickness or PONV and duration of anaesthesia are used to obtain a risk score for 
PONV(20). 
 
APFEL’S RISK SCORE 
 
In a study by Apfel et el, it was concluded that women, patients with previous emetic 
experiences postop, travel sickness, individuals who do not smoke and administration of 
opioid medications after surgery were predictive of PONV. 
 
The occurrence of emesis in the postoperative period was predicted as 10% for an Apfel 
score of 0, 21% for a score of 1, 39% for a score of 2, 61% for a score of 3 and 79% for a 
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score of 4(79,80). An Apfel’s risk score of 2-3 for PONV indicates high risk and a score 
of more than 3 is considered very high risk(79). 
 
Another  risk identification for objective assessment of nausea and vomiting suggested by 
Koivuranta et all included  women, patients who experienced emesis postoperatively 
during previous surgeries, travel sickness, increased time of operation and non smoking. 
The predicted incidence of PONV with the presence of 0 to 5 of these factors is 17%, 
18%, 42%, 54%, 74% and 87%(11,34). 
 
A review of 22 studies done earlier was conducted recently to assess how prone the 
individuals are to the occurrence of nausea and vomiting in the postoperative period. In 
that female gender was found to be the strongest patient specific predictor, followed by 
those who experienced emesis during previous operations, travel sickness, individuals 
who do not smoke and younger age. 
 
 The strongest anaesthesia related predictor was the use of volatile anaesthetics and then 
the length of the procedure and use of opioids after surgery were implicated. There was 
insufficient or no support for numerous beliefs like surgery type, phase of the menstrual 
cycle and preoperative fasting status(11).  
 
This risk stratification helps to avoid the potential side effects and the expense of 
prophylactic antiemetics in low risk population(10,32). 
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PREVENTION AND TREATMENT STRATEGIES FOR PONV. 
 
A detailed preanaesthetic history and evaluation will help to identify those individuals who 
will benefit from PONV prophylaxis and enable to plan specific PONV management suitable 
for the patient. The occurrence of nausea and vomiting postoperatively has decreased to 30 % 
presently when compared to the use of older inhalational agents(14). However the occurrence 
is about 80%   in certain high risk populations.  
 
Preventive antiemetics should be administered for patients with moderate to high risk of 
PONV, or if PONV occurrence  would delay their recovery, compromise their surgery or has 
medical consequences and cause unwarranted hospital admission(74). 
 
As no single antiemetic can completely prevent or treat PONV, recently the focus on PONV 
management has been on using different agents which have different sites of action and the 
adoption of multiple management strategies to handle this issue. This maximises the clinical 
efficacy thereby minimising the side effects(10,38). 
 
Various modalities for PONV management can be classified as  
• Pharmacological 
• Non pharmacological 
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  PHARMACOLOGICAL  
 
Receptors causing transmission of impulses leading to emesis include cholinergic 
(muscarinic), dopaminergic (D₂), serotonergic (5-HT₃), histaminergic (H₁) and neurokinin 
(NK 1) systems. To cause disruptionoif sequential neural transmission of emesis, the 
potential targets for the antiemetic drugs are the receptors involved(2,8,9,11). 
 
PHENOTHIAZINES 
 
Phenothiazines are some of the commonly employed antiemetics worldwide. They exert a t 
D₂ dopamine inhibitory action on the chemoreceptor trigger zone with some anticholinergic 
and antihistaminic effect. The aliphatic phenothiazines like chlorpromazine and  
promethezine have lower effect in preventing nausea and vomiting and causing more sedation 
than  prochlorperazine and perphenazine.  Also, the heterocyclic ones have higher incidence 
of extrapyramidal symptoms than the aliphatic phenothiazines(2,38). 
 
Presently, the use of phenothiazines  has fallen out of favour in view of their  high incidence 
of adverse effects such as restlessness, sedation, dizziness, diarrhoea, agitation, central 
nervous system depression and rarely  extrapyramidal symptoms,  hypotension, 
supraventricular tachycardia and neuroleptic syndrome(8,38). They are currently not 
recommended as the first line management of PONV. 
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BUTYROPHENONES 
 
Butyrophenones like droperidol and haloperidol have similar antiemetic and pharmacological 
effectiveness as the phenothiazines. They have stronger D₂ receptor antagonism on the area 
postrema and chemoreceptor trigger zone(2). Their alpha blocking action contributes to their 
sedation and extrapyramidal side effects, although the latter are rare due to the low  dose used 
to treat PONV(38). The clinical efficacy of injection droperidol 0.625 -1.25 mg  given 
intravenously before the end of surgery has been well established(82).  
 
Until recently it has been used widely as a cost effective antiemetic in the management of 
nausea and vomiting in the postoperative period. The IMPACT trail found that  droperidol is 
equally efficacious as ondansetron and dexamethasone in the management of nausea and 
vomiting in the postoperative period(83).  
 
A meta analysis by Leslie and Gan found out that droperidol can safely be used in 
combination with 5 HT₃ antagonists and that they are generally well tolerated and have 
comparable safety profiles(84). However in 2001, a black box warning was issued for 
droperidol by the FDA citing reports of severe cardiac arrhythmias like torsades de pointes 
and rare cases of sudden cardiac death associated with the use of droperidol(85). Although 
since then the use of droperidol has declined precipitously, many anaesthesia providers still 
believe that the warning was not justified and that it still remains a effective, safe and 
economical  antiemetic(85–87). 
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 Neverthless , the warning, along with the recommendations by the FDA that all elective 
surgery patients receiving droperidol should have continous electrocardiographic monitoring 
for 2 to 3 hours following administration has limited its use. 
 
Haloperidol primarily used as an antipsychotic, has weak antiemetic properties  though has a 
faster onset of antiemetic action and a longer half life because it has less affinity than 
droperidol for the D₂ receptors in the chemoreceptor trigger zone and area postrema(38,88). 
 
BENZAMINES 
 
The most popular antiemetic in this class of drugs is metoclopramide which is a procainamide 
derivative and has both central and peripheral antiemetic action. It blocks the D₂ receptors  
centrally at the medullary vomiting centre and peripherally in the bowel(38,88). 
 
This promotes intestinal motility and enhances emptying thus making it useful in cases of 
delayed emptying caused by opioids(2,38,88–90). The common side effects of 
metoclopromide are extrapyramidal symptoms and sedation. Intravenous administration 
sometimes causes hypotension and rarely, supraventricular tachycardia(2,88).  
 
In a previous systematic review it was concluded that metoclopramide 10 mg did not have 
any clinically meaningful effect in the prevention of PONV(91). Here it should be noted that 
this analysis involved various studies with questioned validity done  by the author Yoshitaka 
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Fujii(92,93).  The current guidelines for the prevention of PONV by the Society of 
ambulatory anaesthesia does not include metoclopramide in the management of nausea and 
vomiting in the postoperative period(94).  
 
A recent quantitative systematic review was conducted to study the activity of systemic 
metoclopramide in the management of nausea and vomiting in the postoperative period in 
individuals having various operations. This concluded that metoclopramide in a dose of 10 
mg given intravenously is good in preventing emesis. Hence it is an acceptable substitute to 
other agents employed in the management of nausea and vomiting(95). 
 
CHOLINERGIC ANTAGONISTS 
 
The anticholinergics are among the oldest antiemetic agents used. Both scopolamine 
(hyoscine) and atropine inhibits cholinergic receptorslocated in the pons and cerebrum (96). 
Compounds with selective M₃ and M₅ muscarinic inhibitory activity possess greater action 
against motion sickness(2,88,97).  
 
Atropine and scopolamine, being  tertiary amines cross the blood CSF barrier and has effect 
in emesis postop and in travel sickness. However, compared to scopolamine, atropine has 
weaker antiemetic properties (38,88) and because of its cardiovascular effects it is generally 
not used as an antiemetic in the postoperative period(98). Scopolamine inhibits transmission 
from the vestibular system to the cntral structures involved in vomiting(88,97). 
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 The common side effects of the use of anticholinergics are dry mouth, sedation, memory 
loss, mydriasis, disorientation, confusion, blurred vision, urinary retention and 
hallucinations(2,88). 
 
 Most studies on the use of scopolamine in PONV have investigated transdermal scopolamine 
(TDS) patch designed to release 1.5 mg over a 3 day period. White et al compared 
preoperative TDS patch 1.5 mg and ondansetron 4mg or droperidol 1.25 mg given during the 
end of operation and found that preoperative TDS patch was as effective as ondansetron or 
droperidol in the management of early and late PONV(104). The high occurrence of 
anticholinergic side effects of scopolamine limits its use as a stand alone antiemetic agent. 
 
 It may be better to use scopolamine in addition to the routinely used antiemetic agents. In a 
study by  Sah, he concluded that when preoperative TDS patch was combined with 
intraoperative ondansetron, there was a marked decrease in the nausea in the first postop day 
when compared to those who received a placebo patch and ondansetron only(99). The 
incidence of anticholinergic side effects was not statistically significant with TDS patch, 
suggesting that scopolamine may be a safe and effective adjunct in PONV management 
especially when used in combination with ondansetron(106). 
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ANTIHISTAMINES 
 
The antihistamines such as diphenhydramine, dimnehydrinate, cyclizine, promethzine and 
doxylamine exert antiemetic properties by blocking the histamine H₁ receptors in the nucleus 
tractus solitarius, at the vomiting centre and the vestibular system with little or no direct 
effect at the chemoreceptor trigger zone(2,88,100). These compounds are particularly useful 
in the prophylaxis and treatment of emesis following middle ear surgery, vertigo and motion 
sickness(2,88).  
 
The common side effects of antihistamines are excessive sleep , dimness of vision, dryness of  
mouth and urinary stasis and are due to their anticholinergic activity. Although antihistamines 
are readily available and inexpensive, their use in the management of PONV has not been 
well studied so far.  
 
In the prevention and treatment of PONV and motion sickness,  cyclizine and promethazine 
have equal efficacy. The most common disadvantage of cyclizine is the excess sedation. In a 
placebo controlled trial comparing the efficacy of ondansetron and cyclizine intravenously in 
daycare gynaecological laparoscopic surgeries , it was found that  both ondansetron and 
cyclizine were comparable in causing a  reduction in  the occurrence of moderate to severe 
nausea and vomiting postoperatively. Also, the need for administration of rescue drug was 
lower in the cyclizine group(101).  
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In a meta analysis of 18 controlled trials done by Kranke et al, they reported that the use of 
dimenhydrinate in the dose of 1mg/kg  as prophylaxis, decreases nausea and vomiting in 
children and in adults upto 48 hours after surgery. They concluded that dimenhydrinate is a  
clinically relevant inexpensive drug with antiemetic efficacy(102). However, the optimal time 
of administration, the dose response, benefit of repetitive doses and estimation of side effects 
need to be evaluated further. 
 
 Promethazine, a phenothiazine  is a potent antiemetic used for the prophylaxis and treatment 
of motion sickness. It has both antihistaminic and anticholinergic activity with a longer 
duration of action, thus preferable to scopolamine. Its major drawbacks are sedation and 
prolonged recovery from anaesthesia(88). 
 
SEROTONIN ANTAGONISTS 
 
Serotonin or 5HT₃ receptor antagonists (5HT₃RAs) are popularly used agents against emesis 
in the postoperative period. (103).  Since its introduction in the early 1990s in  the treatment 
of emesis caused by chemotherapeutic agents, serotonin receptor antagonists have become 
one of the cornerstones in the management of emesis particularly during the postoperative 
period.  
 
47 
 
 Serotonin occurs in high levels in the bowel and in the central nervous system and when 
released, they stimulate the vagal afferent neurons or the chemoreceptor trigger zone to 
activate the vomiting centre(100).  
 
The serotonin receptors are found in abundance in the CTZ and in the nucleus  of the solitary 
tract and is highly selective for nausea and vomiting. Although there are many types of 
serotonin receptors, the 5HT₃ receptor subtype appears in greatest concentration in the 
nucleus of the solitary tract, in the medullary vomiting area all of which have a significant 
action in coordinating the vomiting reflex(38,104).  
 
The 5HT₃ receptor antagonists include ondansetron, granisetron, dolasetron, ramosetron, 
tropisetron and palanosetron. They exhibit their antiemetic action on the serotonin receptor 
rich areas in the brain. In general, all the serotonin receptor antagonists are effective, safe, 
non sedative, well tolerated  and similar,  side effect profiles(103,105–107).  
 
The most common side effects are dizziness, headache, constipation and diarrhoea which are 
of mild to moderate intensity and usually occurs short term(38,108). In view of the differing 
chemical structure of each drug, they exhibit slight differences in the dose response, receptor 
binding affinity and the duration of action(38,109).  
 
 Ondansetron, as the prototypical 5HT₃RA, is the most widely studied among this class of 
drugs and the first report of its use in PONV was published in 1990. Since then several 
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studies have reported its efficacy and safety in the management of PONV. A Cochrane 
systematic review concluded that ondansetron decreases the risk of emesis by 45%  compared 
to the placebo(110). The review found no evidence for the differing risk of PONV for groups 
based on the timing of administration. 
 
 Controversy exists as to whether ondansetron in doses greater than 4 mg offers any greater 
benefit in PONV prophylaxis(111–114). However, ondansetron 4 mg administered 
intravenously before the completion of surgery is the recommended dose for clinical practice 
and is provento be decrease emesis postoperatively(94). The major limitation is that it’s half 
life is 4 hours and hence it is not likely to confer protection to patients after a few hours 
postoperatively (9). Most of the available studies suggest that 5HT₃RAs are most effective 
when administered before  the end of the surgical procedure(115–117). However, one study 
suggests that dolasteron when given during the time of induction of anaesthesia is equally 
effective  in preventing PONV(118).  
 
Unlike ondansetron, the other serotonin receptor antagonists  have linear dose response 
curves with greater clinical effect being achieved with increasing doses until the maximal 
effective dosage is reached(119). The recommended granisetron dose for PONV prophylaxis 
is 0.3 to 1.5 mg I.V (94,120,121). The recommended dolasetron dose for PONV management  
is 12.5 mg administered I.V towards the completion of the operative procedure(94).  
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Though 5HT₃ receptor antagonists have widespread use and are perceived to be well 
tolerated, they are associated with QTc prolongations, cardiac arrhythmias and cardiac 
arrest(122–124). Palonosetron, the newest 5HT₃RA does not affect the QTc interval(125). 
 
 Recently it was found that palosetron has unique receptor binding properties. Unlike the 
other drugs in its class which exhibit simple bimolecular binding, palonosetron causes 
antagonism of the remote binding site. This results in longer antiemetic efficacy. Due to this 
positive receptor binding characteristics and a long half life of 40 hours,  palonosetron given 
intravenously in the dose of 0.25 mg is proven to be effective in preventing delayed emesis 
induced by chemotherapeutic agents (126–128). In the management of PONV, palonosetron 
in a much lesser strength of 0.075 mg successfully reduces the incidence over a 72 hour 
period(125).  
 
Among this class of drugs, ondansetron, granisetron and dolosetron are available as 
intravenous and oral preperations. In addition, ondansetron is also available as oral 
disintegrating tablets which are as effective as the intravenous preparations(129).  
 
In the research of 5HT₃ RAs, a relatively new but growing field is the pharmacogenomics. 
This class of drugs are metabolised by the cytochrome P450 enzyme-CYP2D6 isoform  in the 
liver. Differences in the levels  or activity of this CYP2D6 isoform have an effect on the 
clinical efficacy or pharmacokinetics of this drug(109).  
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Another study by Reuffert et al found that genetic variation in the serotonin receptor subunits, 
HTR3A, HTR3B were implicated with an enhancing risk of an individual developing 
postoperative emesis(130). Though this pharmacogenomic research is in its early stages and 
is of limited use in clinical practice currently, in the future it may provide greater insight into 
the assessment of individual patient riskfor emesis in the postoperative period. 
 
CORTICOSTEROIDS 
 
Dexamethasone is an effective antiemetic proven to be useful in the management of PONV. 
The actual mechanism of its effect is yet unknown. The reasons suggested are blockade of 
prostaglandins in the periphery with enhancement of serotonin inhibition in the central 
nervous system (8,10,15,38).  
 
Glucocoricoids are found to exert several effects on the brain like regulation of receptor 
densities, neurotransmitter concentrations, neuronal configuration and signal 
transduction(131).  
 
Several receptors are present in the nucleus of the solitary tract and the area postrema 
(131,132). Dexamethasone may also exert its antiemetic action through these nuclei. 
Dexamethasone, due to its cost effectiveness and its long duration of action is an attractive 
choice. It is used in doses of 8-10 mg I.V (8,133) for the management of PONV but there are 
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reports that smaller doses of 2-2.5mg are effective(79,134).  Side effects are not documented 
with doses used in PONV management.  
 
 Dexamethasone is particularly effective when used in combination with 5HT₃RAs as it may 
inhibit release of serotonin in the GIT, reduce the serotonin levels by depleting its precursor 
tryptophan and sensitise the 5HT₃ receptors to other antiemetics(133). Hence dexamethasone 
is a valuable addition to combination therapy(83). According to Wang et al, dexamethasone 
was most effective when administered at the commencement of anaesthesia when compared 
to administering it towards the completion of the procedure. (135).  
 
Karanicolas et al did a systematic review and meta-analysis of 17 trials and concluded  that 
dexamethasone  causes 41 % decrease in nausea, 59 % decrease in vomiting and 45 % 
decrease in both nausea and vomiting compared to the placebo. The incidence of headache 
and dizziness were found to be similar between the 2 groups. They also reported that higher 
doses of dexamethasone were significantly more potent than lower  doses (136). This finding 
was consistent with an earlier study done by Elhakim et al who concluded that 
dexamethasone in a dose of 8 mg when combined with ondansetron provided maximal 
antiemetic effect(137). 
 
 However, the society for  ambulatory anaesthesia recommendations for the management of 
postoperarive emesis administers a prophylactic dose of 4 to 5 mg of dexamethasone at 
induction which seems to be equally potent as ondansetron in the management of nausea and 
vomiting in the postoperative period(94). This recommendation is given after a through 
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analysis on the minimum dosage needed for effective prevention of nausea and vomiting 
postoperatively. (133). 
 
NEUROKININ-1 (NK1) RECEPTOR ANTAGONISTS 
 
Tachykinins are neuropeptides which cause contraction of smooth muscles and they share a 
common C-terminal sequence Phe-Xaa-Gly-leu-MetNH₂. These compounds are substance P, 
neurokinin A and neurokinin B.  These exert their biological activity through NKI, NK2 and 
NK3 receptors which are G-protein coupled receptor subtypes(8,145). The NK1 receptor 
mediates the activity  encoded by C-terminal sequence according to the Montreal 
nomenclature.  
 
Substance P  causes antagonism of NK1 receptor. This has an important role in emesis by 
acting as a ligand to the above mentioned receptors (103,138). This substance P is 
competitively inhibited by neurokinin-1 receptor antagonists (NK-1 RAs) and are believed to 
halt neurotransmission in the vomiting centre thereby curbing nausea and vomiting 
centrally(139). Thus it is an good technique to inhibit vomiting by administering a drug 
which has inhibitory action on the vomiting centre. (8). A possible contribution from 
peripheral sites to its action has been suggested(140). This hypothesis is yet to be 
confirmed(8).  
 
 
In view of their action in the final potential commonroute, the NK1RAs possess a wider 
range of activity in preventing nausea and vomiting than 5HT₃RAs, corticosteroids and 
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anticholinergics. The efficacy of this class of drugs is optimised by combining it with other 
different classes of antiemetics(8). Similar to serotonin receptor antagonists, aprepitant does 
not cause sedation, but unlike most serotonin receptor antagonists, it has a half life of 9 to 12 
hours. Also, it is not associated with QTc prolongation(103,141).  
 
 
Aprepitant, the first FDA approved highly selective nonpeptide NK-1RA was shown 
effective against opioid induced emesis  and a large reduction in vomiting and nausea 
compared to ondansetron(138,142,143). It crosses the blood-brain barrier and exerts its 
antiemetic action by blocking substance P in the dorsal vagal complex and area 
postrema(138). 
 
The bioavailability of aprepitant after a single oral dose is approximately 65 %. It has  95% 
protein binding and the mean Vdss is 70 litres in humans. It is metabolised by the liver 
(CYP450 3A4 enzymes). Excreted is both in the faeces and urine. Therefore co 
administration of aprepitant with medications that induce or inhibit this enzyme activity can 
cause  reduced or increased blood levels of aprepitant respectively. Medications known to 
induce or inhibit CYP3A4 should be used with caution(144). 
 
  
Aprepitant induces the activity of CYP2C9.  Hence co administration of aprepitant with drugs 
like warfarin and tolbutamide which are metabolised by the same enzyme causes a decrease 
in blood levels of these drugs.  
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Dosage adjustment is not required for elderly, patients with renal, liver impairment. It is not 
studied in patients with severe liver failure and in children. When co-administered with 
hormonal contraceptives, their efficacy is decreased for approximately one month after using 
aprepitant. It is not recommended  for continous chronic use since it has not been studied so 
far(145). 
 
 For the prevention ofemesis caused by chemotherapeutic agents, aprepitant is prescribed for 
3 days which includes a 5HT₃ antagonist and corticosteroid. The recommended dose is 125 
mg orally on the first day and 80 mg once a day for the next 2 days. Injection fosaprepitant 
dimeglumine is a prodrug of aprepitant. It can be given IV instead of the  oral preparation and 
given in the dose of 115 mg which equals 125 mg of the  oral drug. This is adminisrered as an  
intravenous infusion over 15 minutes. This prodrug is converted to aprepitant in about 15 
minutes(8).  
 
From an analysis of findings from 2 RCTs with aprepitant, Diemunsch and colleagues 
compared 40 mg  of oral aprepitant with 125 mg given within 3 hours before induction of 
anaesthesia and showed similar or slightly reduced effect in the latter. Hence 40 mg of 
aprepitant given within 3 hours prior to anaesthesia is the recommended regimen. 
 
 
 Side effects of aprepitant  include pruritis, headache, fatigue and  dizziness. Some also 
experience constipation and fever. No serious side effects are reported so far. (8,153). 
 
 The first clinical study of NK1RAs in the prevention emesis in the postoperative period was 
published in 1999(146). In a pooled analysis of clinical trials by Apfel et al, they illustrated 
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that  aprepitant was able  to reduce the incidence of emesis when compared to the commonly 
used antiemetics(141).  
 
A randomized double blinded phase 3 trial was cperformed  by Diemunsch et al in patients 
undergoing open abdominal operations comparing single dose aprepitant was better 
compared to ondansetron in preventing emesis  in the first 2 postoperative days. (144). 
 
 In a study on patients undergoing total joint arthroplasty, Dilorio concluded that  aprepitant 
given preoperatively decreased the severity and incidence ofemesis postoperatively,  
shortened the length of hospital stay and reduced the need for additional rescue 
antiemetics(147).   
 
Its specific advantages include its oral preparation, easy to administer for prevention as a 
capsule, the availability of injection  form which can possibly be used for patients who cannot 
tolerate orally, chances of reserving other different  effective antiemetics for 2 nd line 
management since a different class is required in case of emesis despite prophylaxis and its 
longer duration of action. (148).   
 
Earlier studies have shown that compared to monotherapy with ondansetron and other 
antiemetic drugs, multimodal approach is much superior in PONV management. Hence it is 
still not sure if aprepitant will be better than combination or multimodal treatment for 
prevention of emesis postoperatively(83).  
 
Other area for NK1 RAs are rheumatoid arthritis, anxiety, schizophrenia, neural injury, 
stroke, migrane, pain, asthma and  bowel disease (9,148). Another area of interest is in 
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preventing adhesions following laparoscopy by instillation of  aprepitant 
intraperitoneally(149). 
 
 Data from various studies have confirmed theeffectiveness of  NK1RAs in man in nausea 
and vomiting caused by chemotherapeutic agents and in the postoperative period. (150).  
 
 
The investigational NK1RAs  are vofopitant,. casopitant, maropitant, rolapitant, and 
vestipitant(8). The newer NK1 antagonists such as  casopitant and rolapitant  have a longer 
half-life of up to 120 hours but are not approved by the FDA so far(151,152). As this group 
of drugs are the most effective class of antiemetics available, they should be considered for 
patients who have a very high risk of PONV and the medical complications associated with 
vomiting(141).  
 
EPHEDRINE 
 
Ephedrine is a indirectly acting  sympathomimetic drug which helps in prevention of travel 
sickness and postoperative emesis induced by orthostatic hypotension and fluid dehydration. 
Ephedrine helps to maintain the blood pressure thereby prevent the nausea associated with 
hypotension that can occur potoperatively(10). Rothenberg et al, concluded that the 
antiemetic activity of ephedrine was similar to droperidol without any centrally mediated side 
effects in patients undergoing outpatient laparoscopic gynaecological surgery(153). 
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PROPOFOL 
 
It has been observed that patients who receive propofol for induction tend to have less 
postoperative nausea and vomiting(154). The antiemetic effect of propofol may be mediated 
by the influence of gamma-aminobutyric acid on the serotonin system the exact mechanism 
of which is not known. It may directly act on the neurons of the area postrema via the 
GABA(A) receptor to reduce their activity  and depleting  serotonin levels in the CSF and 
brain. (155).The minimum effective concentration of propofol for the prevention emesis 
postoperatively is 300 ng per ml(156). 
 
 
 A systematic review  of randomised control trial by Tramer et al concluded that propofol has 
some beneficial effect on PONV only  when used for maintenance of anaesthesia and has no 
beneficial effect when used only as an induction agent(66). This observation is supported by 
several meta-analyses which concluded that occurrence of PONV is greater in patients who 
receive volatile agents when compared to those who had total intravenous anaesthesia with 
propofol(157,158). 
 
 
 Since inhalational anaesthetics are major factors in nausea and vomiting soon after the 
completion of surgery , the most marked decrease in the occurrence of emesis due to use of 
TIVA with propofol is seen in the first 2 hours after the operation(138). It is not yet proven if 
this advantage of TIVA can extend into the late hours postoperatively(110,150).  
 
 
58 
 
Recent studies have suggested that total intravenous anaesthesia with propofol alone may not 
be an optimal strategy for the prophylaxis of PONV. In a randomized trial done by White et 
al, found that there were no significant differences between those patients who received 
dolosetron  prophylaxis and those who received TIVA  in the incidence of early PONV. 
Hence the investigators suggest that although TIVA with propofol and dolosetron  may be 
similar in the occurrence of emesis in the early postoperative period,  the effects of TIVA 
may be short lived in offering protection against late PONV and in day care surgeries(159). 
 
 
 Over the past few years, use of TIVA with propofol has become popular especially for day 
care surgeries(38). One of the major limiting factors for the use of TIVA continues to be the 
increased expense involved, as economic analyses on the use of TIVA have suggested that it 
is not generally cost effective for PONV prophylaxis(160–162). Nevertheless in high risk 
patients, TIVA with propofol is still a reasonable option especially in high risk patients.  
 
 
CLONIDINE 
 
The antiemetic effect of clonidine is considered to be multifactorial. The significant reduction 
in the requirements of volatile anaesthetics caused by clonidine could reduce the incidence of 
anaesthesia related PONV. 
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 A considerable reduction in the sympathetic outflow caused by clonidine also contributes to 
the reduced incidence of PONV since catecholamine release caused by high sympathetic tone 
triggers nausea and vomiting. The analgesic effect contributed by clonidine can also 
influence the PONV incidence(163).  
 
In a study done by Taheri et al, found that oral clonidine premedication considerably reduced 
the incidence of PONV in patients having day care ear surgical procedures. (164). In a double 
blinded randomized placebo controlled study by Mubarak et al to investigate the effect of 
clonidine on PONV in patients undergoing surgery for breast cancer, found that co induction 
with clonidine caused marked decrease in the incidence of PONV compared to placebo(163). 
In another study by Handa and Fujii in paediatric strabismus surgery patients they reported 
that oral clonidine premedication considerably enhances the antiemetic efficacy of propofol 
in the prevention of PONV(165). Sedation, hypotension, bradycardia and delayed recovery 
from anaesthesia are the possible side effects.  
 
BENZODIAZEPINES 
 
Benzodiazepines possess anxiolytic, sedative and anaesthetic properties. They reduce the 
anaesthesia and surgery related anxiety hence reducing  the incidence of emesis in the 
postoperative period. They do not seem to have true antiemetic receptor binding properties, 
but decreases the anxiety related catecholamine production, thus contributing to the decrease 
in the incidence of PONV(53,166). 
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COMBINED ANTIEMETIC THERAPY 
 
The presently available drugs against emesis are not effective as monotherapy. Since the 
etiology is multifactorial and involves many different receptors, antagonizing only one 
receptor type is not sufficient in many of the patients.  
 
The administration of antiemetics  which act on one type of receptor typically decreases the 
incidence of PONV by 30 % (12). Hence the concept of balanced antiemesis was introduced 
which involves  combining antiemetics which act at various receptor types which 
significantly decreases the incidence of PONV(2,63,88,167).   
 
Many different antiemetic combinations have been studied, which often includes a 5HT3 
receptor antagonist with a corticosteroid or dopamine antagonist(24,168–172). 
 
MULTIMODAL MANAGEMENT STRATEGIES  
 
The potential for implementation of multimodal therapy in PONV prevention was first 
demonstrated by Scuderi et al(173). Since the causes of postoperative nausea and vomiting 
are multifactorial such as patient related, surgical and anaesthesia related risk factors, an 
approach that goes beyond the use of regular antiemetic drugs alone or in combination needs 
to be followed to achieve a more holistic prevention of PONV.  
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A multimodal management of emesis postoperatively includes medications and various 
strategies which start prior to surgery and continues in the intraoperative period (45). The 
preoperative strategies include anxiolysis with benzodiazepines(174,175), preoperative 
administration of dexamethasone(176,177), aprepitant(142,144) and adequate preoperative 
hydration(178).  
 
The intraoperative approach commences with minimising the factors which promote the 
occurrence of emesis postop. This includes the use of regional anaesthesia (179), employing 
propofol for induction and maintanence as total intravenous anaesthesia instead of 
inhalational anaesthetics and nitrous oxide(173), adequate hydration with crystalloids and 
colloids (180,181) and use of short acting opioids intraoperatively as part of TIVA which 
does not increase the occurrence of emesis postop(182).  
 
Post operatively optimal balance should be achieved between opioid use and analgesia since 
pain itself causes PONV and opioids given as part of the postoperative analgesia management 
also causes significant   PONV.  
 
The ultimate objective is to achieve good pain relief with the minimal use of opioids. 
NSAIDS have opioid sparing effects thus significantly reduces the incidence of PONV(183–
186). Ketamine in minimal doses enables to decrease opioid use. (187) This causes a decrease 
in emesis postoperatively.  ( 188). The above strategies in addition to the intraoperative use of 
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more that one antiemetic according to the risks of the individuals greatly reduces the 
occurrence of emesis postoperatively. (177). 
 
NON PHARMACOLOGICAL TECHNIQUES 
 
ACUPUNCTURE 
 
Acupuncture  stimulation of P6 (pericardium 6) is suggested as one of the 
nonpharmacological modalities of PONV management. This acupuncture point pericardium 6 
(Nei guan), the sixth point on the pericardial meridian. This is situated approximately 5 cm 
proximal to the wrist. 
 
 The Cochrane database concluded that acupoint stimulation of P6 would prevent emesis 
postoperatively in 20 % of patients who have a risk of 70 % (189). The variations of 
traditional acupuncture such as acupressure, manual acupuncture, laser acupuncture and 
trancutaneous electrical acupoint stimulation reduces PONV compared to a placebo(190).  
 
AROMATHERAPY 
 
Aromatherapy has been tried in the management of established emesis, but presently there is 
insufficient evidence that it is effective. This uses the inhalation of essential oils and other 
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substances which includes isopropyl alcohol and peppermint oil to alleviate physical and 
emotional symptoms. 
 
 A Cochrane review concluded that isopropyl alcohol was more effective compared to saline 
placebo in PONV, but less effective than the standard antiemetic therapy. Presently there is 
no reliable evidence on the use of peppermint oil(191). 
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                                      PATIENTS AND METHODS 
 
 
This is a double blinded, randomized clinical control trial, approved by the ethics and 
research committee of our institution. 
 
INCLUSION CRITERIA 
 
  ASA (American Society of Anaesthesiology) physical status 1 and 2 
 Female patients 
 Age 18 to 65 years 
 Scheduled for thyroidectomy / mastectomy. 
 
EXCLUSION CRITERIA 
 
Patients who are receiving antiemetics 
 Patients on steroid medication 
 Patients on drugs known to cause emesis currently or in the immediate past 
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Patients with known hypersensitivity to ondansetron or aprepitant 
 Pregnant and nursing mothers 
  
  
A few days before the surgery, the details of the study were explained to the eligible patients 
and a detailed information sheet was given to them. On the day before the surgery, an 
informed consent was obtained from those who were willing to participate in the study. 
 
The randomization schedule was a computer generated random sequence, done by the 
biostatistician who was not involved with the study. On the day of the surgery, patients were 
randomized to receive one of the 2 antiemetic treatments: oral aprepitant 40 mg capsule 
within 3 hours of the anticipated induction of anaesthesia or injection ondansetron 8 mg I.V 
(4 ml) towards the end of surgery and 2 more doses in the ward at 8 hourly intervals. Double 
blinding was done with matching placebos. 
 
 A  pharmacist who  was not involved in the study prepared aprepitant 40 mg capsules, 
placebo matching aprepitant capsules, injection ondansetron 8 mg (4 ml) vials and matching 
saline placebo vials. 
 
The anaesthesia technique included optimal premedication  and standard anaesthetic agents. 
 
66 
 
The patient was shifted to the post anaesthesia care unit, monitored for 1 hour and later 
shifted to the ward. Other antiemetic medications  were prohibited prophylactically  within 24 
hours of surgery. Only rescue therapy was offered on patient request, persistant nausea or an 
emetic episode.  
 
The type of rescue medication was left to the discretion of the post operative care provider. 
The duration of anaesthesia and timing of all the emetic episodes and rescue medications 
given post operatively were recorded. 
 
 An independent investigator unaware of the patient’s randomization collected the data.  
 
Using a  verbal rating scale , patients graded  nausea from 0 (no nausea) to 10 (nausea as bad 
as it could be) at 0-2, 2-12 and 12-24 hours after the operation. 
 
Nausea was defined as an uncomfortable feeling that leads to a tendency to vomit.  
Retching was defined as an effort to vomit which is not under voluntary control and that does 
not cause expulsion of stomach contents.  
 Vomiting was defined as a expulsion of stomach contents.  
An emetic episode was described  as a single retch or vomit or any number of continuous 
vomits or retches.  
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At 24 hours, patients were asked about their satisfaction with the control of nausea and 
vomiting using a 5 point scale. 
 
5 – very satisfied 
4 – somewhat satisfied 
3 – neither satisfied or dissatisfied 
2 – somewhat dissatisfied 
1 – very dissatisfied 
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                                       SETTING OF THE STUDY 
 
This study was carried out in the department of Anaesthesiology, Christian Medical College 
and Hospital, Vellore, which is a tertiary care hospital. The subjects were selected from 
among those patients posted for elective surgery by the department of Endocrine surgery. 
 
                                                    STUDY DESIGN 
 
 The two groups in this study were group 1 who received injection ondansetron and capsule 
placebo and  group 2 who received capsule aprepitant  and injection placebo. The protocol is 
as follows.  
 
GROUP 1 
 
Cap. Placebo within 1 hour preoperatively 
 Inj. Ondansetron 4 ml (8 mg) in the post operative period every 8 hours - 3 doses. 
 (1st dose was given in theatre at the end of surgery & the next 2 doses were given in the 
ward). 
 
Since most of the patients included in our study had a BMI of more than 25, we administered 
injection ondansetron 8 mg (comparable to a dose of 0.1mg/kg). 
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 GROUP 2 
 
 
Cap. Aprepitant within 1 hour preoperatively (along with the pre medication) 
 Inj. Placebo 4 ml in the post operative period every 8 hours - 3 doses 
(1st dose was given in theatre at the end of surgery & the next 2 doses were given in the 
ward). 
 
METHOD OF RANDOMIZATION  
 
Block randomization- a computer generated random sequence was done by biostatistician and 
forwarded directly to the pharmacist for preparation. 
 
METHOD OF ALLOCATION CONCEALMENT 
 
 After approval by the institutional review board, the bulk drug  Aprepitant 10 grams was purchased 
from Dr.Reddy’s laboratories through Pharmacy and were be packaged as capsules of 40 mg each 
since Cap.Aprepitant in the dose of 40 mg was not available in the market. Drugs were prepared in 
the pharmacy special preparation lab in our institution. Double blinding was maintained with 
matching placebos.  
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BLINDING AND MASKING  
 
Double blinded - Participant, Investigator and outcome assessor were blinded. 
 
PRIMARY OUTCOME 
 
Incidence of post operative vomiting. 
 
SECONDARY OUTCOMES 
 
 Severity of post operative nausea, number of episodes of  vomiting, timing of the first 
vomiting episode, use of rescue antiemetics.  
 
TARGET SAMPLE SIZE AND RATIONALE 
 
 60 in each group 
 The required sample size to show a difference in the proportion of post operative vomiting 
between aprepitant and ondansetron was found to be 60 in each arm with 80% power and at 
5% level of significance with an anticipated post operative nausea of 14% and 36% in the 
aprepitant and ondansetron respectively. 
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Formula: 
 =
(/	 + )
	2
	
 
P = average proportion of vomiting from both the groups 
Q = 1 – P 
d = difference in the two proportions 
/	  is the standard normal deviate at 5% level of significance 
 is the standard normal deviate for 80% power (192) 
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                                           STATISTICAL METHODS 
 
 
The primary outcome in this study is the occurrence of vomiting. Chi square test was used to 
compare this outcome variable between the two groups  to determine the statistical 
significance. 
 
Similarly, the secondary outcomes in study which includes severity of postoperative nausea, 
number of episodes of vomiting and use of rescue antiemetics are compared between the two 
groups using chi-square tests. 
 
The other parameters like the duration of anaesthesia and the timing of the first vomiting 
episode were compared between the two groups using Mann-Whitney non parametric test. 
 
Data analysis was performed using the software SPSS 14.0 and Microsoft Office Excel 2007. 
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                                                    RESULTS 
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The two groups in this study are group 1 who received injection ondansetron and capsule 
placebo and group 2 who received capsule aprepitant and the placebo injection. The protocol 
is as follows. 
  
GROUP 1 
 
 
Cap. placebo within 1 hour preoperatively and  
 Inj. Ondansetron 4 ml (8 mg) in the post operative period every 8 hours - 3 doses. 
 (1st dose was given in theatre at the end of surgery & the next 2 doses were given in the 
ward). 
 
 GROUP 2 
 
 
Cap.Aprepitant within 1 hour preoperatively (along with the pre medication) and 
 Inj.placebo 4 ml in the post operative period every 8 hours - 3 doses 
(1st dose was given in theatre at the end of surgery & the next 2 doses were given in the 
ward). 
 
 
In this study there were 62 patients in group 1 and 63 patients in group 2 making a total of 
125 patients. Out of this 125 patients, 5 patients were excluded from the study after 
randomisation, since they required unanticipated intensive care or high dependency unit 
admissions or required intraoperative steroids which will influence the assessment of 
antiemetic efficacy. 
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AGE DISRIBUTION AND BODY MASS INDEX 
 
 
 125 patients were recruited for this study, the age and BMI of the participants in both groups 
matched. 
 
 
Age group in 
years 
Group 1 
(n=62) 
Group 2 
(n=63) 
Total  
(n=125) 
Less than 29 10 8 18 
30 - 39 13 13 26 
40 - 49 23 20 43 
50 & above 16 22 38 
BMI Group 1 
(n=59) 
Group 2 
(n=61) 
Total  
(n=120) 
Less than 25 26 27 53 
25 - 29 22 22 44 
30 & above 11 12 23 
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DIAGNOSIS 
 
The distribution of diagnoses in both groups were similar, carcinoma breast being the 
commonest followed by various thyroid diseases. 
 
 
 
 
 
 
 
 
 
                                        
 
0
5
10
15
20
25
30
35
40
carcinoma 
breast
carcinoma 
thyroid
multinodular 
goitre
thyroid nodule pagets disease thyroiditis
group 1
group 2
77 
 
                                      OPERATION DONE 
 
 
The commonest surgery was modified radical mastectomy 72 cases followed by total 
thyroidectomy 38 cases, and these were equally distributed in both groups. The graph below 
shows the surgical procedures undergone by the patients in group 1 and group 2 
 
 
 
 
 
 
 
DURATION OF ANAESTHESIA 
The median duration of anaesthesia was 115 minutes in group 1 and 110 minutes in group 2. 
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              EMETIC EPISODES IN THE 24 POSTOPERATIVE HOURS 
 
Postop 
hours 
             
               0 – 2 
 
              2 - 12 
 
            12 - 24 
Emetic 
episodes 
Group 1 
(n=59) 
Group 2 
(n=61) 
Group 1 
(n=59) 
Group 2 
(n=61) 
Group 1 
(n=59) 
Group 2 
(n=61) 
0 47 52 51 52 59 58 
1 – 2 11 9 6 7 0 3 
> 2 1 0 2 2 0 0 
P value             0.49                0.97               0.23 
 
 
In the immediate postoperative period, 79.7%  in ondansetron group and 85.2% in aprepitant 
group were free of emesis. A smaller number 18.7% and 14.7% respectively had one emetic 
episode. Only one patient had more than 2 episodes of vomiting  in the ondansetron group. 
The P value in this period is 0.49 which indicates that both ondansetron and aprepitant are 
equally effective in the immediate postoperative period. 
 
In the 2 to 12 hour period postoperatively, both the groups displayed similar statistics, 86.4% 
in the ondansetron group and 85.2% in the aprepitant group did not have vomiting. Both 
groups had similar number of patients, vomiting score of 1 – 2 (grp 1n=6, grp 2 n=7) and 
more than 2(n=2 in both groups). The P value of 0.97 is not significant. 
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After 12 hours, the  ondansetron group did better. Most patients in both groups were free of 
vomiting and 3 patients in the aprepitant group had 1-2 episodes of vomiting. The P value of 
0.23 is not significant indicating that both the drugs were equally effective in the 1st 
postoperative day. 
 
 
VERBAL RATING SCALE FOR NAUSEA IN THE 24 POSTOPERATIVE HOURS 
 
Postop 
hours 
 
              0 - 2 
 
           2 - 12 
 
             12-24 
VRS for 
nausea 
Group 1 
(n=59) 
Group 2 
(n=61) 
Group 1 
(n=59) 
Group 2 
(n=61) 
Group 1 
(n=59) 
Group 2 
(n=61) 
0 47 51 48 46 57 57 
1-2 2 2 3 4 1 1 
>2 10 8 8 11 1 3 
P value                  .84                  .73                .62 
 
 
In the first 2 hours after surgery, both the groups had similar verbal rating score for nausea, 
79.7% in ondansetron group and 83.6% in aprepitant group were free of nausea.  2 patients in 
both the groups had a score of 1-2. But a larger number, 17% in ondansetron group and 
13.1% in aprepitant group had nausea score of more than 2. 
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In 2-12 hours of postoperative period, 81.4% in ondansetron group and 75.4% in aprepitant 
group did not experience nausea. Similar number of patients in both the groups( n=3 in grp 1 
and n=4 in grp 2)  had nausea score of 1-2. 
 
In the 12-24 hour period, similar number of patients in both the groups were free of nausea 
(n=57 in both groups). Nausea score of 1-2 were also similar in both the groups (n=1). 
However 1 patient in ondansetron group and 3 patients in aprepitant group had a nausea score 
of more than 2.  
 
The P value  for both groups were not significant for nausea in the first postoperative day, 
with the ondansetron group doing slightly better than the aprepitant group. 
 
PEAK NAUSEA SCORE IN THE FIRST 24 POSTOPERATIVE HOURS 
 
Verbal rating score of postoperative nausea between 1 and 3 is rated mild and between 4 and 
7 is rated moderate and more that 8 is considered severe in a scale of 0  to 10. 
 
 
Peak nausea 
score 
Group1 
(n=59) 
Group 2 
(n=61) 
Total 
(n=120) 
P value 
0 39 37 76  
.406 Mild  7 14 21 
moderate 13 10 23 
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Of the 120 patients, 21 of them had mild nausea and 23 had moderate nausea indicating that 
38.3% of total number of cases experienced mild to moderate nausea. 
 
 
TIMING OF 1ST VOMITING & USE OF RESCUE ANTIEMETIC ( in hours postop ) 
 
 
 Timing of 1 st emesis 1 st rescue antiemetic 
Group 1 
(n=17) 
Group 2 
(n=18) 
Group 1 
(n=9) 
Group 2 
(n=16) 
Median(hours) 01:30 02:40 01:00 02:27 
 
 
In group 1, the first episode of vomiting occurred within a median duration 90 minutes 
postoperatively. Similarly it 160 minutes in  group 2. 
 
The average time to ask for rescue antiemetic was 60 minutes in group 1 and 147 minutes in 
group 2. 
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SATISFACTION WITH THE CONTROL OF PONV 
 
 
5- very satisfied, 4- somewhat satisfied, 3- neither satisfied or dissatisfied, 2- somewhat 
dissatisfied, 1- very dissatisfied. 
 
 
Satisfaction rating Group 1   
(n=59)       
Group 2 
(n=61) 
Total 
(n=120) 
 
P value 
1 1                    1                  2                  
 
.676 
2 3                    2                  5                 
3 4                    4                  8               
4 9                   16                25              
5 42                 38                80               
 
 
 105 patients  (87.5%)  inclusive of both groups were satisfied with the intervention for 
PONV. An equal number of 4 patients (3.3%)  in both groups were non committal in their 
opinion. A small number comprising of 7 patients (5.8%) were dissatisfied with the PONV 
management. Both the groups displayed good PONV management, hence the P value of 
0.676 is insignificant. 
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                                               DISCUSSION 
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This study found that the antiemetic efficacy of 5HT₃ antagonist, ondansetron and 
neurokinin-1 antagonist, aprepitant was comparable in preventing PONV in patients 
undergoing thyroidectomy and mastectomy. 
 
 All the 120 patients included had an Apfel’s simplified risk score of 2 to 3 indicating high 
risk and received volatile anaesthetics, increasing the PONV incidence to 60 to 80 %.  The 
demographic variables like age and body mass index were comparable in both groups. 
   
Both ondansetron and aprepitant were equally efficacious in preventing emetic episodes, 
decrease in nausea and delayed time to ask for rescue antiemetic. The possible reasons for 
both these drugs to be comparable could be because aprepitant 40 mg was given as a single 
oral dose and injection ondansetron 8 mg was given in 3 doses, 8 hours apart, in the first post 
operative day.  
 
Aprepitant has an elimination half life of 9-12 hours and hence administered once daily as 
compared to 5-7 hours for ondansetron. Since ondansetron was the standard antiemetic in our 
practice, we chose to compare it with aprepitant. Both these drugs have dissimilar half lives, 
hence it would be unethical to administer a single dose of ondansetron postoperatively. 
 
The outcome in our study is not statistically significant and shows that a single oral  dose of 
aprepitant isequally effective to  injection ondansetron  given eight hourly over a 24 hour 
period. 
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 Though statistically not significant, the aprepitant group had a higher incidence of vomiting 
in the 12-24 hour period, but took longer to have the first episode of vomiting and also to 
receive the first dose of rescue antiemetic.  
 
Ondansetron group though marginally fared better, had more individuals with nausea. Of the 
total recruits in the study , 87.5% of them were satisfied with the PONV control, 5.8% were 
dissatisfied and 3.3% had non committal opinion indicating that both groups were equally 
effective, offering good patient satisfaction.  
 
We disagree with Diemunsch et al who studied 922  individuals who had open abdominal 
operationsand found that one oral dose of aprepitant 40 mg or 125 mg were more effective 
than a single dose of ondansetron 4 mg I.V in preventing vomiting at 24 and 48 hours after 
surgery(144). We also disagree with Gan et al who conducted a study with similar doses of   
both the drugs and concluded that aprepitant was better than ondansetron in preventing 
vomiting in the first 24 to 48 hours(142). We agree with both the authors above who 
concluded that ondansetron was not inferior to aprepitant in preventing nausea, timing of  
first vomiting episode and in the use of rescue antiemetics.  
 
In a recent study by Jung et al on postoperative analgesia with fentanyl- based PCA after 
gynaecological laparoscopy, quoted that oral aprepitant 80 mg was more efficacious in 
lowering the incidence of PONV in the first 48 hours after surgery. This study also showed a 
trend towards a more complete response in patients who received aprepitant 125 mg group, 
though the difference was not statistically significant(193).  
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Considering its proven efficacy in preventing acute and delayed emesis caused by 
chemotherapeutic agents in doses of 125 mg on the first day and 80 mg each for the next 2 
days, the role of doses higher than 40 mg in PONV management should be considered 
especially in high risk patients. We were limited to the use of oral aprepitant 40 mg as it is the 
approved dose by the Drug Controller General of India for PONV. 
 
Neurotransmitter receptor systems involved in transmission of impulses causing nausea and 
vomiting include cholinergic (muscarinic), dopaminergic (D₂), serotonergic (5-HT₃), 
histaminergic (H₁) and neurokinin (NK 1) systems. Hence targeting one particular receptor 
may not confer complete protection against PONV. NK-1RAs may be combined with 
antiemetics from other classes for optimal efficacy. Thus inclusion of aprepitant to 
multimodal PONV therapy will have positive attributes of long half-life, lack of sedation, no 
QTc prolongation and effective prevention of PONV. 
 
Though aprepitant is more expensive than the commonly used antiemetics, the traditional 
ones are limited in their antiemetic efficacy and their side effects. The routine use of 
aprepitant to prevent PONV may be expensive. It should be limited to patients at high risk of 
PONV such as high risk surgeries, risk of severe complications of PONV, hyper-reaction to 
opioids or anaesthetics, unsuccessful treatment with low-cost antiemetics or a past history of 
severe PONV and in multimodal antiemetic therapy. 
 
More research is required in determining the optimal dose of neurokinin-1 receptor 
antagonists in PONV prophylaxis and treatment, the rescue schemes, their interaction with 
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other antiemetics, possible role of pharmacogenomics in the variation of individual response 
to PONV and their use in pregnancy, nursing mothers and in paediatric population. 
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                                                LIMITATIONS 
 
In this study, we did not include a placebo group and hence the incidence of PONV in 
patients who did not receive any prophylaxis was not known. However, since a high risk 
patient population was chosen in this study, we felt it was inappropriate to include a placebo 
group. The dosage of aprepitant was limited to 40 mg as recommended by the Drug controller 
General of India for PONV use. We did not conduct a cost effective analysis in the 
prophylactic use of oral aprepitant.  
 
The rescue antiemetic was not standardised in our study. It was left to the discretion of the 
postoperative care giver.  Hence those in the ondansetron group could have received 
ondansetron as rescue drug. Repeated dosing of ondansetron as rescue drug is not 
recommended in those already on ondansetron as prophylaxis(194), this may have influenced 
a small subset of patients in our study.  
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                                                  CONCLUSIONS 
 
 
A single dose of oral aprepitant has comparable effects to injection ondansetron administered 
eighth hourly in preventing PONV, the severity of nausea, number of rescue antiemetics and 
the time to first emetic episode in the 24 hour postoperative period. 
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                                         APPENDIX 
   
PATIENT INFORMATION SHEET                                       
Department of Anaesthesia 
CMC hospital Vellore, Tamilnadu 
Informed consent form no ............... 
 
The title of my research is “comparing the efficacy of Ondansetron vs Aprepitant to prevent Nausea 
and Vomiting after surgery”. 
Person carrying out research: Dr........................... 
I’m Dr......................, a senior registrar working in the department of Anaesthesia, CMC Vellore. I’m 
doing a research study comparing two medications used in preventing vomiting after surgery. 
I am going to give you information and invite you to be part of this research. You do not have to 
decide today whether or not you will participate in the research. Before you decide, you can talk to 
anyone you feel comfortable with about the research.  
There may be some words that you do not understand. Please ask me to stop as we go through the 
information and I will take time to explain.  If you have questions later, you can ask me or the 
anaesthetist on the day of surgery. 
Purpose of the research: 
The chance of having nausea or vomiting after surgery is around 30 % despite treatment. I intend to 
study an oral medication called ‘Aprepitant’ to prevent vomiting after surgery. We generally give 
injection ondansetron to prevent vomiting after surgery.  
You are being requested to participate in a study comparing the antiemetic efficacy of either 
Aprepitant  40 mg given in a capsule form within 3 hours before surgery or Ondansetron 8 mg given 
as an intravenous injection at the end of the surgery and at regular intervals in the first 24 hours after 
the operation. 
One of the above mentioned medications will be given to you based on random allocation in either 
group. You will receive either of the drugs not both. If further nausea and vomiting occurs in the post 
operative period, you will receive prompt treatment for the same. 
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After the operation I will be reviewing you in the ward for complaints of nausea and vomiting. 
The benefits of both these medications include relief of post operative nausea and vomiting after 
anaesthesia. The side effects of these medications include occasional headache, constipation and 
itching. However, theses side effects are rare and the benefits outweigh the side effects significantly. 
I plan to include patients who undergo surgery on the thyroid and breast in this hospital. Your 
participation in this study is purely voluntary and you can withdraw from the study at any time, even 
immediately before the surgery. Your refusal to participate will not involve any penalty or loss of 
benefits to which you are otherwise entitled. If you choose not to participate in this research project, 
you will receive the routine treatment for vomiting offered in this hospital. 
Confidentiality: your name will not be mentioned anywhere neither the data sheet nor the final 
published study. Your data will bear a study number and the number will be used till analysis. The 
master sheet will have your study number.  
Reimbursements: You will not be charged the cost of Ondansetron or Aprepitant. There are no other 
incentives.  
 Sharing of the result:  the results of research are property of Christian medical college and I'm 
entitled to publish it in a journal or present in a conference. 
This proposal has been reviewed and approved by [IRB, Christian Medical College], which is a 
committee whose task it is to make sure that research participants are protected from harm.   
If you wish to find about more about the IRB,  
contact  
Research Office, 
second floor, 
Carman block,  
Christian Medical College,  
Bagayam, Vellore 632002.  
Email: research@cmcvellore.ac.in, telephone: 04162284294.  
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It has also been reviewed by the Ethics Review Committee CMC Vellore, which is supporting the 
study.  
In case of doubts or questions, please contact Dr........................, Department of Anaesthesia, 
Christian Medical College and Hospital, Vellore. Ph.No. ................ 
 
 CERTIFICATE OF CONSENT 
 
 I have read the foregoing information/ it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction.  I consent voluntarily to participate as a participant in this research. 
Print Name of Participant__________________            
Signature of Participant ___________________             
Date ___________________________                             
              Day/month/year                                                                                      
     
If illiterate Thumb impression (R / L) 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
Print name of witness_____________________             AND         Thumb print of participant 
Signature of witness ______________________ 
Date ________________________ 
                Day/month/year 
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Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
1. Capsule Aprepitant or placebo will be given prior to the surgery. 
2. Injection Ondansetron or placebo will be given at the end of surgery. 
3. Participation is voluntary and cost of ondansetron or aprepitant will be borne by the 
research fund. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent_______________________ 
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________  
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PROFORMA FOR POST OPERATIVE NAUSEA AND VOMITING STUDY 
 COMPARING ONDANSETRON AND APREPITANT 
 
NAME:                                                      AGE/SEX:                       H.NO:                                 
SL. NO: 
ASA     :   1     /    2            HT:                WT:                                  BMI:                                  
DATE: 
RISK FACTORS FOR PONV: FEMALE GENDER 
                                               NON SMOKING STATUS 
                                               H/O PONV / MOTION SICKNESS 
                                               POST OP OPIOID USE 
DIAGNOSIS: 
OPERATION DONE: 
PREMEDICATION- DRUG/TIME: 
 
TIME OF COMMENCEMENT OF OPERATION:                        DURATION OF 
ANAESTHESIA: 
PONV  
                                                              FIRST 2 HOURS            2-12 HOURS                       
12-24 HOURS 
NO OF EMETIC EPISODES 
NAUSEA      -MILD 
                    -MODERATE 
                   -SEVERE 
      
PEAK NAUSEA SCORE AND TIMING: 
 
TIME TO FIRST VOMITING: 
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TIME TO FIRST USE OF RESCUE ANTIEMETIC: 
 
NO. OF TIMES RESCUE ANTIEMETIC GIVEN IN 24 HOURS: 
 
SATISFACTION WITH CONTROL OF PONV: 
 
VERY SATISFIED (5) 
SOMEWHAT SATISFIED (4) 
NEITHER SATISFIED OR DISSATISFIED (3) 
SOMEWHAT DISSATISFIED (2) 
VERY DISSATISFIED (1) 
 
VERBAL RATING SCORE FOR POST OP NAUSEA  - SCALE OF 0-10  
 
 
 0 - NO NAUSEA  
10 –NAUSEA  AS BAD AS IT COULD BE 
 
MILD              – 0 TO 3 
MODERATE – 4 TO 7 
     SEVERE         – 8 TO 10                  
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                                              STUDY PROTOCOL 
 
This is a double blinded, randomized clinical control trial, approved by the ethics and 
research committee of our institution. All ASA 1 and 2 female patients, aged 18 to 65 years 
scheduled for thyroidectomy and mastectomy are eligible for the study. Patients who are 
receiving antiemetics or steroid medication or drugs known to cause emesis currently or in 
the immediate past, patients with known hypersensitivity to ondansetron or aprepitant, 
pregnant and nursing mothers, patients on medications known to induce CYP3A4 such as 
phenytoin, carbamazepine, barbiturates, rifampicin, rifabutin, or CYP3A4 inhibitors 
(clarithromycin, ketoconazole, itraconazole),and those known to be CYP3A4 substrates 
(terfenadine, pimozide, cisapride or astemizole) are excluded from the study. On the day 
before the surgery, an informed consent is obtained from those who are willing to participate 
in the study. 
Patients will be randomized into 2 groups - 60 patients in each group. The randomization 
schedule is a computer generated random sequence, done by the biostatistician who is 
otherwise not involved with the study. 
STUDY GROUP 
C.Aprepitant within 1 hour preoperatively (along with the pre medication) 
 Inj.placebo 4 ml in the post operative period every 8 hours - 3 doses 
(1 st dose will be given in theatre at the end of surgery & the next 2 doses will be given in the 
ward). 
CONTROL GROUP 
C.placebo within 1 hour preoperatively 
 Inj. Ondansetron 4 ml(8 mg) in the post operative period every 8 hours - 3 doses. 
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(1 st dose will be given in theatre at the end of surgery & the next 2 doses will be given in the 
ward).  
 
Prevention of Postoperative Nausea and Vomiting (PONV) 
The recommended oral dosage of Aprepitant  is 40 mg within 1 to 3 hours prior to induction 
of anesthesia. 
DCGI approval 
Aprepitant 40mg capsules 
(additional strength) 
Prevention of post-operative 
nausea & vomiting (additional 
indication) 
24.04.07 
 
ADVERSE REACTIONS 
Clinical adverse experiences for the Aprepitant  PONV regimen are: constipation, nausea, 
pruritus, pyrexia, headache, fatigue, dizziness. There were no serious adverse drug-related 
experiences reported in the postoperative nausea and vomiting clinical studies in patients 
taking 40 mg aprepitant. 
DRUG INTERACTIONS 
Aprepitant is a substrate for CYP3A4; therefore, coadministration  with drugs that inhibit or 
induce CYP3A4 activity may result in increased or reduced plasma concentrations of 
aprepitant respectively. 
  
Aprepitant is an inducer of CYP2C9; therefore, coadministration  with drugs that are 
metabolized by CYP2C9 (e.g. warfarin,tolbutamide), may result in lower plasma 
concentrations of these drugs . 
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                                                  DATA SHEET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
serial no. group age sex hospi. no ASA height weight BMI
1 1 28 1 125528f 1 145 50 22.8
2 2 49 1 087559f 2 148 53 24.2
3 2 53 1 186521f 1 153 60 25.6
4 1 35 1 030494f 1 158 49 19.6
5 1 26 1 831144b 1 155 61 25.4
6 2 45 1 091301c 2 155 61 25.4
7 2 38 1 952148d 1 156 60 24.7
8 1 33 1 715380d 2 151 53 23.2
9 2 57 1 171441f 2 144 59 28.5
10 1 65 1 193313f 1 157 56 22.7
11 1 44 1 093006f 2 158 79 31.6
12 2 55 1 114040f 2 150 70 31.1
13 1 60 1 181941f 2 151 59 25.9
14 2 47 1 129537f 1 140 55 28.1
15 1 49 1 115841f 1 152 65 28.1
16 2 45 1 188268f 1 154 54 22.8
17 2 56 1 195844f 1 141 56 28.2
18 1 62 1 188570f 2 152 65 27.7
19 1 55 1 192579f 2 144 60 28.9
20 2 58 1 167700f 2 152 60 26
21 1 54 1 132035f 1 143 55 26.9
22 2 34 1 250129d 2 156 75 30.8
23 2 58 1 351427d 2 155 65 27.1
24 1 39 1 143998f 1 150 60 26.7
25 2 60 1 393046c 1 158 77 30.8
26 1 46 1 186137f 2 152 78 33.8
27 2 28 1 196276f
28 1 46 1 145517f 1 155 56 23.3
29 1 46 1 129795f 1 152 70 30.3
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30 2 40 1 130104f 2 152 61 26.4
31 1 44 1 138732f 1 154 60 25.3
32 2 36 1 138679f 1 162 87 33.2
33 2 37 1 141490f 2 145 67 31.9
34 1 36 1 150188f 2 154 64 27
35 1 35 1 103148f 2 152 70 34.2
36 2 65 1 900843d 2 140 51 26
37 1 41 1 149857f 1 154 68 28.7
38 2 48 1 176457f 1 147 81 37.5
39 1 64 1 125212f 2 145 54 25.7
40 2 25 1 146674f 1 152 56 24.2
41 1 37 1 087319f
42 1 25 1 127537f 2 143 55 26.9
43 2 36 1 840891d 1 150 73 32.4
44 2 51 1 109116f 1 143 50 24.5
45 2 45 1 155524f 2 155 65 27.1
46 1 18 1 185130f 1 156 45 16.8
47 2 28 1 217131f 1 155 65 27.1
48 1 55 1 150744f 1 152 48 20.8
49 2 51 1 952117d 1 154 40 16.9
50 2 55 1 171358f 2 150 55 24.4
51 1 42 1 746733c 2 150 47 20.9
52 1 31 1 203021f 2 155 51 21.2
53 2 38 1 167105f 2 159 48 19
54 2 47 1 181018f 1 147 40 18.5
55 1 39 1 179873f 1 156 45 18.5
56 1 58 1 225023f 2 156 64 26.3
57 2 26 1 224280f 2 152 42 18.2
58 1 51 1 192113f 2 151 65 28.5
59 2 49 1 047680f 2 145 59 28.1
 
 
116 
 
sl no. Risk 1 risk  2 risk  3 risk  4 diagnosis operation pre med p m time
1 1 1 2 2 1 1 1 12:00:00
2 1 1 2 2 1 1 1 14:00:00
3 1 1 2 2 1 1 1 10:40:00
4 1 1 2 2 1 1 2 07:10:00
5 1 1 2 2 4 2 2 15:05:00
6 1 1 2 2 2 2 3 12:10:00
7 1 1 2 2 3 2 1 15:20:00
8 1 1 2 2 4 3 4 16:55:00
9 1 1 2 2 1 1 1 09:55:00
10 1 1 2 2 1 1 5 14:40:00
11 1 1 2 2 1 1 3 18:00:00
12 1 1 2 2 3 2 2 14:40:00
13 1 1 2 2 1 1 5 08:15:00
14 1 1 2 2 2 2 1 06:40:00
15 1 1 2 2 1 1 3 08:10:00
16 1 1 2 2 1 1 1 10:00:00
17 1 1 2 2 1 1 2 11:30:00
18 1 1 2 2 5 4 2 13:40:00
19 1 1 2 2 1 1 2 16:00:00
20 1 1 2 2 2 2 5 06:35:00
21 1 1 2 2 1 1 1 12:30:00
22 1 1 2 2 4 2 2 11:25:00
23 1 1 2 2 1 1 2 06:30:00
24 1 1 2 2 1 1 2 13:30:00
25 1 1 2 2 1 1 2 16:00:00
26 1 1 2 2 1 1 4 11:25:00
27
28 1 1 2 2 1 1 3 11:00:00
29 1 1 2 2 1 1 2 06:30:00
 
117 
 
30 1 1 2 2 4 3 5 14:25:00
31 1 1 2 2 2 2 5 14:35:00
32 1 1 2 2 1 1 1 10:20:00
33 1 1 2 2 1 1 2 08:15:00
34 1 1 2 2 3 2 1 06:25:00
35 1 1 2 2 2 3 3 10:15:00
36 1 1 2 2 3 2 1 06:30:00
37 1 1 2 2 1 1 5 08:45:00
38 1 1 2 2 1 1 5 10:00:00:00
39 1 1 2 2 1 1 2 14:25:00
40 1 1 2 2 3 2 5 12:40:00
41
42 1 1 2 2 1 1 1 13:45:00
43 1 1 2 2 3 2 3 15:30:00
44 1 1 2 2 1 1 5 09:00:00
45 1 1 2 2 1 1 2 06:55:00
46 1 1 2 2 2 2 2 15:00:00
47 1 1 2 2 4 3 5 12:45:00
48 1 1 2 2 1 1 5 06:40:00
49 1 1 2 2 4 3 1 13:30:00
50 1 1 2 2 2 2 2 11:15:00
51 1 1 2 2 1 1 1 06:30:00
52 1 1 2 2 2 2 2 14:30:00
53 1 1 2 2 2 2 2 10:30:00
54 1 1 2 2 1 1 1 13:00:00
55 1 1 2 2 3 2 3 06:30:00
56 1 1 2 2 1 1 1 13:00:00
57 1 1 2 2 6 2 2 08:25:00
58 1 1 2 2 1 1 3 10:30:00
59 1 1 2 2 1 1 5 06:30:00
118 
 
30 15:30:00 02:00:00 0 0 0 0
31 15:35:00 02:25:00 1 0 0 2
32 11:15:00 01:40:00 0 0 0 0
33 09:25:00 01:45:00 2 0 0 5
34 07:20:00 02:20:00 0 0 0 0
35 10:45:00 01:30:00 0 0 0 0
36 07:30:00 02:50:00 0 0 0 0
37 10:30:00 01:45:00 0 0 0 0
38 11:10:00 02:10:00 0 2 0 0
39 16:00:00 02:05:00 1 0 0 4
40 13:30:00 02:20:00 0 0 0 0
41
42 14:55:00 02:35:00 1 3 0 5
43 17:30:00 02:00:00 0 1 0 0
44 10:50:00 01:55:00 0 0 0 0
45 07:30:00 01:50:00 1 3 0 2
46 17:15:00 02:05:00 2 0 0 4
47 15:45:00 01:45:00 0 0 0 0
48 07:30:00 01:45:00 0 0 0 0
49 14:30:00 01:20:00 0 0 0 0
50 12:30:00 02:00:00 0 0 0 0
51 07:30:00 01:45:00 0 0 0 0
52 15:45:00 02:45:00 0 0 0 0
53 12:00:00 01:45:00 0 0 0 0
54 14:00:00 01:15:00 0 0 0 0
55 07:30:00 01:50:00 0 4 0 0
56 13:30:00 02:15:00 0 0 0 0
57 09:15:00 02:30:00 0 0 0 4
58 12:00:00 00:40:00 0 0 0 0
59 07:30:00 02:00:00 0 5 0 0
 
 
119 
 
94 14:30:00 01:50:00 0 0 0 0 0
95 14:30:00 01:50:00 0 0 0 0 0
96 07:30:00 02:00:00 0 0 0 0 0
97 15:00:00 01:30:00 2 0 0 4 0
98 16:45:00 01:15:00 0 0 0 0 0
99 17:00:00 02:25:00 0 0 2 0 0
100 09:30:00 01:15:00 0 0 0 0 0
101 07:30:00 01:30:00 0 0 0 0 0
102 15:00:00 02:00:00 0 0 0 0 0
103 10:15:00 01:15:00 0 2 0 0 4
104 10:55:00 01:35:00 0 0 0 0 0
105 09:00:00 01:45:00 1 0 0 3 0
106 13:00:00 01:15:00 0 0 0 0 0
107 09:00:00 01:30:00 0 2 0 0 3
108 10:30:00 01:30:00 0 0 0 0 0
109 07:30:00 01:30:00 0 0 0 0 2
110 11:20:00 02:10:00 0 0 0 0 0
111 13:50:00 02:10:00 0 0 0 0 0
112 15:40:00 01:55:00 2 0 0 4 0
113 07:25:00 01:25:00 0 0 0 0 3
114 14:45:00 02:05:00 1 0 0 4 0
115 17:05:00 01:40:00 0 0 0 0 0
116 10:55:00 01:40:00 0 1 0 0 3
117
118 16:10:00 01:45:00 0 0 0 0 0
119 14:00:00 05:20:00 1 0 0 5 0
120 13:30:00 01:35:00 0 0 0 0 0
121
122 10:45:00 01:00:00 0 0 0 0 0
123 12:30:00 01:05:00 0 0 0 0 0
124
125 09:45:00 01:30:00 0 0 0 0 0
120 
 
sno vrsn12_24 pns n12_24 vt_1 pns_t vt_1 res1 res_24 res24 satis
60 0 0 0 5
61 0 2 05:30:00 1 4
62 0 0 0 5
63 0 0 0 5
64 0 0 0 5
65 0 0 0 5
66 0 4 01:55:00 01:40:00 01:55:00 1 3
67 0 0 0 5
68 0 0 0 5
69 0 0 0 5
70 0 0 0 5
71 0 0 0 5
72 0 0 0 5
73 0 0 0 5
74 0 0 0 5
75 0 0 0 5
76 4 4 07:00:00 05:00:00 09:30:00 1 2
77 0 0 0 5
78 0 0 0 5
79 0 0 0 5
80 0 0 0 5
81 0 5 01:00:00 01:00:00 01:00:00 1 2
82 0 0 0 5
83 0 0 0 5
84 0 3 00:30:00 00:15:00 00:30:00 0 4
85 0 2 00:40:00 00:40:00 00:40:00 0 4
86 0 0 0 5
87 0 4 00:15:00 00:15:00 00:05:00 1 3
88 0 2 09:00:00 0 4
89 0 4 00:25:00 00:25:00 1 2
90 0 0 0 5
91 0 4 02:15:00 02:15:00 0 3
92 0 3 00:50:00 00:50:00 0 4
93 0 0 0 5
121 
 
94 0 0 0 5
95 0 0 0 5
96 0 0 0 5
97 0 4 01:00:00 01:00:00 01:00:00 1 3
98 0 0 0 5
99 3 3 12:05:00 12:05:00 12:05:00 1 4
100 0 0 0 5
101 0 0 0 5
102 0 0 0 5
103 0 4 06:00:00 06:00:00 06:00:00 2 4
104 0 0 0 5
105 0 3 00:55:00 00:55:00 00:55:00 1 4
106 0 0 0 5
107 0 3 03:00:00 03:00:00 03:00:00 0 4
108 0 0 0 5
109 0 2 03:30:00 2 4
110 0 0 0 5
111 0 0 0 5
112 0 4 00:15:00 00:15:00 00:15:00 1 3
113 0 3 10:10:00 0 4
114 0 4 00:10:00 00:10:00 00:10:00 1 4
115 0 0 0 5
116 0 3 05:25:00 05:25:00 05:25:00 0 4
117
118 0 0 0 5
119 0 5 00:15:00 00:10:00 00:15:00 1 4
120 0 0 0 5
121
122 0 0 0 5
123 0 0 0 5
124
125 0 0 0 5
 
 
 
